,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2012', 'fs': 'May 2012', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztep2AC'}, 'Id': 'a0POZ000002Ztep2AC', 'Event_Date__c': '2012-05-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2012', 'Status_History__c': 'a132P000000Aq14QAC'}, 'change': None}]",May 2012,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2012', 'fs': 'Jun 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 25 June 2012.', 'fs': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 25 June 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Zteq2AC'}, 'Id': 'a0POZ000002Zteq2AC', 'Event_Date__c': '2012-06-25', 'Event_Description__c': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 25 June 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Jun 2012', 'Status_History__c': 'a132P000000Aq3eQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2012', 'fs': 'Aug 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Zter2AC'}, 'Id': 'a0POZ000002Zter2AC', 'Event_Date__c': '2012-08-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2012', 'Status_History__c': 'a132P000000Aq4gQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2012-08.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2012-08.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2012', 'fs': 'Aug 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztes2AC'}, 'Id': 'a0POZ000002Ztes2AC', 'Event_Date__c': '2012-08-02', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2012-08.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Aug 2012', 'Status_History__c': 'a132P000000Aq6cQAC'}, 'change': None}, {'Summary': {'s': 'The Subcommittee noted that there are newly published randomized control trials with regards to micronised progesterone in hormone replacement therapy. The Subcommittee recommended that this application be taken back to PTAC with the newly published trials for reconsideration.', 'fs': 'The Subcommittee noted that there are newly published randomized control trials with regards to micronised progesterone in hormone replacement therapy. The Subcommittee recommended that this application be taken back to PTAC with the newly published trials for reconsideration.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf"" target=""_blank"">Endocrinology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf"" target=""_blank"">Endocrinology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2014', 'fs': 'Jun 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 17 June 2014.', 'fs': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 17 June 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Zteu2AC'}, 'Id': 'a0POZ000002Zteu2AC', 'Event_Date__c': '2014-06-17', 'Event_Description__c': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 17 June 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf"" target=""_blank"">Endocrinology Subcommittee minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'The Subcommittee noted that there are newly published randomized control trials with regards to micronised progesterone in hormone replacement therapy. The Subcommittee recommended that this application be taken back to PTAC with the newly published trials for reconsideration.', 'Formatted_Date__c': 'Jun 2014', 'Status_History__c': 'a132P000000AqiOQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2015', 'fs': 'Nov 2015', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztev2AC'}, 'Id': 'a0POZ000002Ztev2AC', 'Event_Date__c': '2015-11-11', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2015', 'Status_History__c': 'a132P000000Ar2LQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-02-update-2.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-02-update-2.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztew2AC'}, 'Id': 'a0POZ000002Ztew2AC', 'Event_Date__c': '2016-02-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-02-update-2.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar4uQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2021', 'fs': 'Feb 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Endocrinology Subcommittee meeting to provide advice on Tuesday 30 March 2021', 'fs': 'Assigned to Endocrinology Subcommittee meeting to provide advice on Tuesday 30 March 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztey2AC'}, 'Id': 'a0POZ000002Ztey2AC', 'Event_Date__c': '2021-02-19', 'Event_Description__c': 'Assigned to Endocrinology Subcommittee meeting to provide advice on Tuesday 30 March 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2021', 'Status_History__c': 'a132P000000CcRWQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 20 August 2021', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 20 August 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztez2AC'}, 'Id': 'a0POZ000002Ztez2AC', 'Event_Date__c': '2021-06-10', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 20 August 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000DNqBQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztf02AC'}, 'Id': 'a0POZ000002Ztf02AC', 'Event_Date__c': '2021-06-15', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CvZPQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that access to micronised progesterone for menopause hormone therapy be widened by removing the funding restrictions, with a <b>high priority</b>, within the context of treatment of endocrine disease.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation based on:</p><p>1.2.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0A lowered risk of breast cancer, cardiovascular disease, and fluctuations in mood compared to currently funded options</p><p>1.2.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>A lowered risk of clotting and stroke compared to currently funded options for those needing longer term therapies</p><p>1.2.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>A more favourable side-effect profile for those who cannot tolerate currently funded options </p><p>1.2.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0A currently unmet health need for Māori and Pacific women who are more at risk of early menopause and are at a higher risk of adverse events from currently funded options due to a higher incidence of comorbidities.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that access to micronised progesterone for menopause hormone therapy be widened by removing the funding restrictions, with a <b>high priority</b>, within the context of treatment of endocrine disease.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation based on:</p><p>1.2.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0A lowered risk of breast cancer, cardiovascular disease, and fluctuations in mood compared to currently funded options</p><p>1.2.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>A lowered risk of clotting and stroke compared to currently funded options for those needing longer term therapies</p><p>1.2.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>A more favourable side-effect profile for those who cannot tolerate currently funded options </p><p>1.2.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0A currently unmet health need for Māori and Pacific women who are more at risk of early menopause and are at a higher risk of adverse events from currently funded options due to a higher incidence of comorbidities.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that menopause hormone therapy (MHT) is used by a small group of women with moderate to severe symptoms at menopause, the duration of which can last for 8-10 years after the last menstrual period. The Subcommittee noted that currently the MHT consists of oestrogen combined with progestogen for all women with an intact uterus, and that the progestin options in New Zealand have included medroxyprogesterone acetate, norethisterone and dydrogesterone (which was removed in 2010). </p><p><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that menopause can significantly impact on a woman’s quality of life, is associated with lower levels of health status and work productivity and greater use of health resources (<a href=""https://pubmed.ncbi.nlm.nih.gov/28650869/"" target=""_blank"">NAMS Practice Guideline. Menopause. 2017;24:728-53</a>). The Subcommittee also noted that concern was raised about MHT safety in 2002 when a premature release of safety information from the Women’s Health Initiative Study occurred (<a href=""https://pubmed.ncbi.nlm.nih.gov/12360366/"" target=""_blank"">Lemay., J Obstet Gynaecol Can. 2002 Sep;24(9):711-5</a>). The Subcommittee considered that this data was shown subsequently to be incorrect and subsequent more complete analysis showed significant benefits in the younger group of women taking MHT within 10 years of their last menstrual period. The Subcommittee considered this resulted in long-term stigma regarding MHT and that acceptance (and resulting uptake) of MHT among menopausal women is still affected, but has remained relatively stable in recent years.</p><p><br></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that clinical trials have shown that currently funded MHT options pose an increased risk of breast and cardiovascular health complications. The Subcommittee noted that micronised progesterone for MHT has less undesirable effects on cardiovascular, cognitive and breast health than the currently funded options, with no increase in thromboembolic risk, and no increase or attenuated risk of breast cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/17333341/"" target=""_blank"">Fournier et al. Breast Cancer Res Treat. 2008;107:103-11</a><a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">, Dartois et al., Int J Cancer 2016 138, 2415–2427</a>). </p><p><br></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that all new clinical trials are using micronised progesterone as the ‘status quo’ comparator and that it is unlikely that head-to-head data comparing micronised progesterone will become available. The Subcommittee considered new trials using the currently funded agents as the comparators were unlikely, due to trial regulators considering it unethical to conduct a trial where the comparators required are known to increase breast cancer and cardiovascular risk. The Subcommittee also noted that the use of micronised progesterone for MHT is endorsed by international guideline groups, notably the <a href=""https://www.imsociety.org/wp-content/uploads/2020/08/2016-ims-hrt-health-recommendations-english.pdf"" target=""_blank"">International Menopause Society 2016 guidelines</a> which state that modern progestogens, natural progesterone and <span style=""color: rgb(32, 33, 36);"">selective estrogen receptor modulators </span>optimise metabolic and breast effects. The Subcommittee considered almost all new MHT products currently being trialled contain micronised progesterone, given its therapeutic benefits and its place in international guidelines.</p><p><br></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered the unmet health need which would be met by an MHT product that is safe for women to take long-term, as 10-20% of women will have long-term symptoms, and young women with premature ovarian insufficiency will require MHT until the normal age of menopause. The Subcommittee noted that long-term use of MHT using traditional progestin therapy is likely to increase the risk of breast cancer, and in women with additional risk factors and over the age of 60 the risk of deep vein thrombosis increases. The Subcommittee also noted that Māori and Pacific women are over-represented in the group of women at risk of stroke and deep vein thrombosis because of higher incidence of comorbidities such as diabetes, obesity, and hypertension. </p><p><br></p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members were made aware that initial data from the Christchurch Health and Development Study suggests that Māori women are more likely to reach menopause before the age of 40 (ie. early menopause) at six times the rate of non-Māori women. The Subcommittee considered that due to the current cost associated with micronised progesterone (ie. patients self-funding), there is inequitable access to the treatment option currently considered best practice in MHT. </p><p><br></p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the E3N cohort study reported that oestrogen in combination with micronised progesterone was the only option in the study that did not increase the relative risk of breast cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/17333341/"" target=""_blank"">Fournier et al. Breast Cancer Res Treat. 2008;107:103-11</a>). The Subcommittee also noted the result from a more recent analysis for the same cohort, which reported a slight increase in breast cancer risk in the long-term, which however still remains lower than the risk with synthetic progesterone options (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Dartois et al. Int J Cancer. 2016;138:2415-27</a>). The Subcommittee also noted that this study aggregated\xa0progesterone and dydrogesterone effects together, which may have an effect on the risk increase over time. </p><p><br></p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that micronised progesterone for this indication has been previously considered by PTAC and the Endocrinology Subcommittee, and that at the most recent PTAC meeting where this was considered (in 2016) PTAC requested to see new evidence cited by the Subcommittee, the Dartois et al. (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Int J Cancer 2016;138:2415-27</a>) study. The Subcommittee noted that PTAC had not yet reviewed this new evidence. </p><p><br></p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted a meta-analysis from 2017 investigating oestradiol therapy and breast cancer risk in perimenopausal and postmenopausal women, which concluded that the breast cancer risk varies with the type of progestogen included in the treatment regimen (<a href=""https://pubmed.ncbi.nlm.nih.gov/27898258/"" target=""_blank"">Yang et al. Gynecol Endocrinol. 2017;33:87-92</a>). </p><p><br></p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted a meta-analysis of progestogens and venous thromboembolism in menopausal women that concluded there is evidence to show there is no increase in venous thromboembolism risk with the addition of micronised progesterone to transdermal oestrogen compared with norpregnane derivatives (<a href=""https://pubmed.ncbi.nlm.nih.gov/29570359/"" target=""_blank"">Scarabin PY. Climacteric. 2018;21:341-45</a>). </p><p><br></p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>Members were made aware of the following evidence when considering micronised progesterone for MHT:</p><p>1.11.1.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/22024394/"" target=""_blank"">Canonico et al., Maturitas. 2011 Dec;70(4):354-60</a> Progestogens and venous thromboembolism among postmenopausal women using hormone therapy</p><p>1.11.2.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/28898378/"" target=""_blank"">Manson et al., JAMA. 2017 Sep 12;318(10):927-938</a> Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials</p><p>1.11.3.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/27548404/"" target=""_blank"">Palacios et Mejía., Expert Opin Drug Saf. 2016 Nov;15(11):1515-1525</a> Progestogen safety and tolerance in hormonal replacement therapy</p><p>1.11.4.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/28650869/"" target=""_blank"">The NAMS 2017 Hormone Therapy Position Statement Advisory Panel., Menopause. 2017 Jul;24(7):728-753</a> The 2017 hormone therapy position statement of The North American Menopause Society</p><p>1.11.5.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/26872610/"" target=""_blank"">Baber et al., Climacteric. 2016 Apr;19(2):109-50 </a>\xa02016 IMS Recommendations on women’s midlife health and menopause hormone therapy</p><p>1.11.6.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/29583019/"" target=""_blank"">Warren., Climacteric. 2018 Aug;21(4):355-357</a> Vaginal progesterone and the vaginal first-pass effect</p><p>1.11.7.<span style=""font-size: 7pt;""> </span>\xa0<a href=""https://pubmed.ncbi.nlm.nih.gov/29630427/"" target=""_blank"">Mirkin., Climacteric. 2018 Aug;21(4):346-354</a> Evidence on the use of progesterone in menopausal hormone therapy</p><p>1.11.8.<span style=""font-size: 7pt;""> </span><a href=""https://www.imsociety.org/2021/02/25/progestogen-progestin-progesterone-why-all-the-confusion-webinar/"" target=""_blank"">International Menopause Society Webinar. March 23 2021</a>; Progestogens, progestin, progesterone. Why all the confusion? IMS online education module. </p><p>1.11.9.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/22432812/"" target=""_blank"">\xa0Gompel., Climacteric. 2012 Apr;15 Suppl 1:18-25</a>. Micronized progesterone and its impact on the endometrium and breast vs. progestogens</p><p>1.11.10.<span style=""font-size: 7pt;"">\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24223752/"" target=""_blank"">Cordina-Duverger et al., PLoS One. 2013 Nov 1;8(11):e78016</a> Risk of Breast Cancer by Type of Menopausal Hormone Therapy: A Case-Control Study among Post-Menopausal Women in France</p><p><br></p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that micronised progesterone has improved bioavailability compared with currently funded MHT options and can be administered vaginally for those women with side-effects related to systemic use. The Subcommittee also noted that micronised progesterone does not have the adverse interactions with glucocorticoid or androgen receptors that lead to weight gain, bloating, and skin problems which are experienced with the currently funded options. The Subcommittee noted that the median duration of use of micronised progesterone or MHT would be approximately 5 years for most women, and that the majority of patients would likely cease treatment once their severe menopause symptoms subside. </p><p><br></p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, for managing menopausal symptoms, approximately 10% of women at menopause would use MHT and that the numbers of patients prescribed MHT likely includes patients treated for other indications (noting the majority of funded MHT products are not subject to funding restrictions). The Subcommittee considered that this would equate to approximately 25,000 women in New Zealand annually. The Subcommittee considered that if micronised progesterone were to be open listed there would be uptake from a younger age group who are at a higher clotting and stroke risk and for whom currently funded options are not appropriate, such as those who have gone through premature menopause or have hypogonadism. The Subcommittee considered the potential increased usage from indications other than those previously noted would be minimal.</p><p><br></p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the cost associated with open listing micronised progesterone would be minimal, especially when taking into consideration the decrease in breast cancer risk, and that any future economic analysis should include the increased risk in breast cancer for comparator agents.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that menopause hormone therapy (MHT) is used by a small group of women with moderate to severe symptoms at menopause, the duration of which can last for 8-10 years after the last menstrual period. The Subcommittee noted that currently the MHT consists of oestrogen combined with progestogen for all women with an intact uterus, and that the progestin options in New Zealand have included medroxyprogesterone acetate, norethisterone and dydrogesterone (which was removed in 2010). </p><p><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that menopause can significantly impact on a woman’s quality of life, is associated with lower levels of health status and work productivity and greater use of health resources (<a href=""https://pubmed.ncbi.nlm.nih.gov/28650869/"" target=""_blank"">NAMS Practice Guideline. Menopause. 2017;24:728-53</a>). The Subcommittee also noted that concern was raised about MHT safety in 2002 when a premature release of safety information from the Women’s Health Initiative Study occurred (<a href=""https://pubmed.ncbi.nlm.nih.gov/12360366/"" target=""_blank"">Lemay., J Obstet Gynaecol Can. 2002 Sep;24(9):711-5</a>). The Subcommittee considered that this data was shown subsequently to be incorrect and subsequent more complete analysis showed significant benefits in the younger group of women taking MHT within 10 years of their last menstrual period. The Subcommittee considered this resulted in long-term stigma regarding MHT and that acceptance (and resulting uptake) of MHT among menopausal women is still affected, but has remained relatively stable in recent years.</p><p><br></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that clinical trials have shown that currently funded MHT options pose an increased risk of breast and cardiovascular health complications. The Subcommittee noted that micronised progesterone for MHT has less undesirable effects on cardiovascular, cognitive and breast health than the currently funded options, with no increase in thromboembolic risk, and no increase or attenuated risk of breast cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/17333341/"" target=""_blank"">Fournier et al. Breast Cancer Res Treat. 2008;107:103-11</a><a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">, Dartois et al., Int J Cancer 2016 138, 2415–2427</a>). </p><p><br></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that all new clinical trials are using micronised progesterone as the ‘status quo’ comparator and that it is unlikely that head-to-head data comparing micronised progesterone will become available. The Subcommittee considered new trials using the currently funded agents as the comparators were unlikely, due to trial regulators considering it unethical to conduct a trial where the comparators required are known to increase breast cancer and cardiovascular risk. The Subcommittee also noted that the use of micronised progesterone for MHT is endorsed by international guideline groups, notably the <a href=""https://www.imsociety.org/wp-content/uploads/2020/08/2016-ims-hrt-health-recommendations-english.pdf"" target=""_blank"">International Menopause Society 2016 guidelines</a> which state that modern progestogens, natural progesterone and <span style=""color: rgb(32, 33, 36);"">selective estrogen receptor modulators </span>optimise metabolic and breast effects. The Subcommittee considered almost all new MHT products currently being trialled contain micronised progesterone, given its therapeutic benefits and its place in international guidelines.</p><p><br></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered the unmet health need which would be met by an MHT product that is safe for women to take long-term, as 10-20% of women will have long-term symptoms, and young women with premature ovarian insufficiency will require MHT until the normal age of menopause. The Subcommittee noted that long-term use of MHT using traditional progestin therapy is likely to increase the risk of breast cancer, and in women with additional risk factors and over the age of 60 the risk of deep vein thrombosis increases. The Subcommittee also noted that Māori and Pacific women are over-represented in the group of women at risk of stroke and deep vein thrombosis because of higher incidence of comorbidities such as diabetes, obesity, and hypertension. </p><p><br></p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members were made aware that initial data from the Christchurch Health and Development Study suggests that Māori women are more likely to reach menopause before the age of 40 (ie. early menopause) at six times the rate of non-Māori women. The Subcommittee considered that due to the current cost associated with micronised progesterone (ie. patients self-funding), there is inequitable access to the treatment option currently considered best practice in MHT. </p><p><br></p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the E3N cohort study reported that oestrogen in combination with micronised progesterone was the only option in the study that did not increase the relative risk of breast cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/17333341/"" target=""_blank"">Fournier et al. Breast Cancer Res Treat. 2008;107:103-11</a>). The Subcommittee also noted the result from a more recent analysis for the same cohort, which reported a slight increase in breast cancer risk in the long-term, which however still remains lower than the risk with synthetic progesterone options (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Dartois et al. Int J Cancer. 2016;138:2415-27</a>). The Subcommittee also noted that this study aggregated\xa0progesterone and dydrogesterone effects together, which may have an effect on the risk increase over time. </p><p><br></p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that micronised progesterone for this indication has been previously considered by PTAC and the Endocrinology Subcommittee, and that at the most recent PTAC meeting where this was considered (in 2016) PTAC requested to see new evidence cited by the Subcommittee, the Dartois et al. (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Int J Cancer 2016;138:2415-27</a>) study. The Subcommittee noted that PTAC had not yet reviewed this new evidence. </p><p><br></p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted a meta-analysis from 2017 investigating oestradiol therapy and breast cancer risk in perimenopausal and postmenopausal women, which concluded that the breast cancer risk varies with the type of progestogen included in the treatment regimen (<a href=""https://pubmed.ncbi.nlm.nih.gov/27898258/"" target=""_blank"">Yang et al. Gynecol Endocrinol. 2017;33:87-92</a>). </p><p><br></p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted a meta-analysis of progestogens and venous thromboembolism in menopausal women that concluded there is evidence to show there is no increase in venous thromboembolism risk with the addition of micronised progesterone to transdermal oestrogen compared with norpregnane derivatives (<a href=""https://pubmed.ncbi.nlm.nih.gov/29570359/"" target=""_blank"">Scarabin PY. Climacteric. 2018;21:341-45</a>). </p><p><br></p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>Members were made aware of the following evidence when considering micronised progesterone for MHT:</p><p>1.11.1.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/22024394/"" target=""_blank"">Canonico et al., Maturitas. 2011 Dec;70(4):354-60</a> Progestogens and venous thromboembolism among postmenopausal women using hormone therapy</p><p>1.11.2.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/28898378/"" target=""_blank"">Manson et al., JAMA. 2017 Sep 12;318(10):927-938</a> Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials</p><p>1.11.3.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/27548404/"" target=""_blank"">Palacios et Mejía., Expert Opin Drug Saf. 2016 Nov;15(11):1515-1525</a> Progestogen safety and tolerance in hormonal replacement therapy</p><p>1.11.4.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/28650869/"" target=""_blank"">The NAMS 2017 Hormone Therapy Position Statement Advisory Panel., Menopause. 2017 Jul;24(7):728-753</a> The 2017 hormone therapy position statement of The North American Menopause Society</p><p>1.11.5.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/26872610/"" target=""_blank"">Baber et al., Climacteric. 2016 Apr;19(2):109-50 </a>\xa02016 IMS Recommendations on women’s midlife health and menopause hormone therapy</p><p>1.11.6.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/29583019/"" target=""_blank"">Warren., Climacteric. 2018 Aug;21(4):355-357</a> Vaginal progesterone and the vaginal first-pass effect</p><p>1.11.7.<span style=""font-size: 7pt;""> </span>\xa0<a href=""https://pubmed.ncbi.nlm.nih.gov/29630427/"" target=""_blank"">Mirkin., Climacteric. 2018 Aug;21(4):346-354</a> Evidence on the use of progesterone in menopausal hormone therapy</p><p>1.11.8.<span style=""font-size: 7pt;""> </span><a href=""https://www.imsociety.org/2021/02/25/progestogen-progestin-progesterone-why-all-the-confusion-webinar/"" target=""_blank"">International Menopause Society Webinar. March 23 2021</a>; Progestogens, progestin, progesterone. Why all the confusion? IMS online education module. </p><p>1.11.9.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/22432812/"" target=""_blank"">\xa0Gompel., Climacteric. 2012 Apr;15 Suppl 1:18-25</a>. Micronized progesterone and its impact on the endometrium and breast vs. progestogens</p><p>1.11.10.<span style=""font-size: 7pt;"">\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24223752/"" target=""_blank"">Cordina-Duverger et al., PLoS One. 2013 Nov 1;8(11):e78016</a> Risk of Breast Cancer by Type of Menopausal Hormone Therapy: A Case-Control Study among Post-Menopausal Women in France</p><p><br></p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that micronised progesterone has improved bioavailability compared with currently funded MHT options and can be administered vaginally for those women with side-effects related to systemic use. The Subcommittee also noted that micronised progesterone does not have the adverse interactions with glucocorticoid or androgen receptors that lead to weight gain, bloating, and skin problems which are experienced with the currently funded options. The Subcommittee noted that the median duration of use of micronised progesterone or MHT would be approximately 5 years for most women, and that the majority of patients would likely cease treatment once their severe menopause symptoms subside. </p><p><br></p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, for managing menopausal symptoms, approximately 10% of women at menopause would use MHT and that the numbers of patients prescribed MHT likely includes patients treated for other indications (noting the majority of funded MHT products are not subject to funding restrictions). The Subcommittee considered that this would equate to approximately 25,000 women in New Zealand annually. The Subcommittee considered that if micronised progesterone were to be open listed there would be uptake from a younger age group who are at a higher clotting and stroke risk and for whom currently funded options are not appropriate, such as those who have gone through premature menopause or have hypogonadism. The Subcommittee considered the potential increased usage from indications other than those previously noted would be minimal.</p><p><br></p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the cost associated with open listing micronised progesterone would be minimal, especially when taking into consideration the decrease in breast cancer risk, and that any future economic analysis should include the increased risk in breast cancer for comparator agents.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted an application from Pharmaco for the use of micronised progesterone (Utrogestan) for menopause hormone therapy, MHT (previously referred to as hormone replacement therapy, HRT).</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted an application from Pharmaco for the use of micronised progesterone (Utrogestan) for menopause hormone therapy, MHT (previously referred to as hormone replacement therapy, HRT).</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">Endocrinology Subcommittee Records</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">Endocrinology Subcommittee Records</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 30 March 2021.', 'fs': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 30 March 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztf12AC'}, 'Id': 'a0POZ000002Ztf12AC', 'Event_Date__c': '2021-06-28', 'Event_Description__c': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 30 March 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">Endocrinology Subcommittee Records</a></p>', 'Outcome__c': 'High', 'Formatted_Date__c': 'Jun 2021', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that access to micronised progesterone for menopause hormone therapy be widened by removing the funding restrictions, with a <b>high priority</b>, within the context of treatment of endocrine disease.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation based on:</p><p>1.2.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0A lowered risk of breast cancer, cardiovascular disease, and fluctuations in mood compared to currently funded options</p><p>1.2.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>A lowered risk of clotting and stroke compared to currently funded options for those needing longer term therapies</p><p>1.2.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>A more favourable side-effect profile for those who cannot tolerate currently funded options </p><p>1.2.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0A currently unmet health need for Māori and Pacific women who are more at risk of early menopause and are at a higher risk of adverse events from currently funded options due to a higher incidence of comorbidities.\xa0</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted an application from Pharmaco for the use of micronised progesterone (Utrogestan) for menopause hormone therapy, MHT (previously referred to as hormone replacement therapy, HRT).</p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that menopause hormone therapy (MHT) is used by a small group of women with moderate to severe symptoms at menopause, the duration of which can last for 8-10 years after the last menstrual period. The Subcommittee noted that currently the MHT consists of oestrogen combined with progestogen for all women with an intact uterus, and that the progestin options in New Zealand have included medroxyprogesterone acetate, norethisterone and dydrogesterone (which was removed in 2010). </p><p><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that menopause can significantly impact on a woman’s quality of life, is associated with lower levels of health status and work productivity and greater use of health resources (<a href=""https://pubmed.ncbi.nlm.nih.gov/28650869/"" target=""_blank"">NAMS Practice Guideline. Menopause. 2017;24:728-53</a>). The Subcommittee also noted that concern was raised about MHT safety in 2002 when a premature release of safety information from the Women’s Health Initiative Study occurred (<a href=""https://pubmed.ncbi.nlm.nih.gov/12360366/"" target=""_blank"">Lemay., J Obstet Gynaecol Can. 2002 Sep;24(9):711-5</a>). The Subcommittee considered that this data was shown subsequently to be incorrect and subsequent more complete analysis showed significant benefits in the younger group of women taking MHT within 10 years of their last menstrual period. The Subcommittee considered this resulted in long-term stigma regarding MHT and that acceptance (and resulting uptake) of MHT among menopausal women is still affected, but has remained relatively stable in recent years.</p><p><br></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that clinical trials have shown that currently funded MHT options pose an increased risk of breast and cardiovascular health complications. The Subcommittee noted that micronised progesterone for MHT has less undesirable effects on cardiovascular, cognitive and breast health than the currently funded options, with no increase in thromboembolic risk, and no increase or attenuated risk of breast cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/17333341/"" target=""_blank"">Fournier et al. Breast Cancer Res Treat. 2008;107:103-11</a><a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">, Dartois et al., Int J Cancer 2016 138, 2415–2427</a>). </p><p><br></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that all new clinical trials are using micronised progesterone as the ‘status quo’ comparator and that it is unlikely that head-to-head data comparing micronised progesterone will become available. The Subcommittee considered new trials using the currently funded agents as the comparators were unlikely, due to trial regulators considering it unethical to conduct a trial where the comparators required are known to increase breast cancer and cardiovascular risk. The Subcommittee also noted that the use of micronised progesterone for MHT is endorsed by international guideline groups, notably the <a href=""https://www.imsociety.org/wp-content/uploads/2020/08/2016-ims-hrt-health-recommendations-english.pdf"" target=""_blank"">International Menopause Society 2016 guidelines</a> which state that modern progestogens, natural progesterone and <span style=""color: rgb(32, 33, 36);"">selective estrogen receptor modulators </span>optimise metabolic and breast effects. The Subcommittee considered almost all new MHT products currently being trialled contain micronised progesterone, given its therapeutic benefits and its place in international guidelines.</p><p><br></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered the unmet health need which would be met by an MHT product that is safe for women to take long-term, as 10-20% of women will have long-term symptoms, and young women with premature ovarian insufficiency will require MHT until the normal age of menopause. The Subcommittee noted that long-term use of MHT using traditional progestin therapy is likely to increase the risk of breast cancer, and in women with additional risk factors and over the age of 60 the risk of deep vein thrombosis increases. The Subcommittee also noted that Māori and Pacific women are over-represented in the group of women at risk of stroke and deep vein thrombosis because of higher incidence of comorbidities such as diabetes, obesity, and hypertension. </p><p><br></p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>Members were made aware that initial data from the Christchurch Health and Development Study suggests that Māori women are more likely to reach menopause before the age of 40 (ie. early menopause) at six times the rate of non-Māori women. The Subcommittee considered that due to the current cost associated with micronised progesterone (ie. patients self-funding), there is inequitable access to the treatment option currently considered best practice in MHT. </p><p><br></p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the E3N cohort study reported that oestrogen in combination with micronised progesterone was the only option in the study that did not increase the relative risk of breast cancer (<a href=""https://pubmed.ncbi.nlm.nih.gov/17333341/"" target=""_blank"">Fournier et al. Breast Cancer Res Treat. 2008;107:103-11</a>). The Subcommittee also noted the result from a more recent analysis for the same cohort, which reported a slight increase in breast cancer risk in the long-term, which however still remains lower than the risk with synthetic progesterone options (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Dartois et al. Int J Cancer. 2016;138:2415-27</a>). The Subcommittee also noted that this study aggregated\xa0progesterone and dydrogesterone effects together, which may have an effect on the risk increase over time. </p><p><br></p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that micronised progesterone for this indication has been previously considered by PTAC and the Endocrinology Subcommittee, and that at the most recent PTAC meeting where this was considered (in 2016) PTAC requested to see new evidence cited by the Subcommittee, the Dartois et al. (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Int J Cancer 2016;138:2415-27</a>) study. The Subcommittee noted that PTAC had not yet reviewed this new evidence. </p><p><br></p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted a meta-analysis from 2017 investigating oestradiol therapy and breast cancer risk in perimenopausal and postmenopausal women, which concluded that the breast cancer risk varies with the type of progestogen included in the treatment regimen (<a href=""https://pubmed.ncbi.nlm.nih.gov/27898258/"" target=""_blank"">Yang et al. Gynecol Endocrinol. 2017;33:87-92</a>). </p><p><br></p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted a meta-analysis of progestogens and venous thromboembolism in menopausal women that concluded there is evidence to show there is no increase in venous thromboembolism risk with the addition of micronised progesterone to transdermal oestrogen compared with norpregnane derivatives (<a href=""https://pubmed.ncbi.nlm.nih.gov/29570359/"" target=""_blank"">Scarabin PY. Climacteric. 2018;21:341-45</a>). </p><p><br></p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>Members were made aware of the following evidence when considering micronised progesterone for MHT:</p><p>1.11.1.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/22024394/"" target=""_blank"">Canonico et al., Maturitas. 2011 Dec;70(4):354-60</a> Progestogens and venous thromboembolism among postmenopausal women using hormone therapy</p><p>1.11.2.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/28898378/"" target=""_blank"">Manson et al., JAMA. 2017 Sep 12;318(10):927-938</a> Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials</p><p>1.11.3.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/27548404/"" target=""_blank"">Palacios et Mejía., Expert Opin Drug Saf. 2016 Nov;15(11):1515-1525</a> Progestogen safety and tolerance in hormonal replacement therapy</p><p>1.11.4.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/28650869/"" target=""_blank"">The NAMS 2017 Hormone Therapy Position Statement Advisory Panel., Menopause. 2017 Jul;24(7):728-753</a> The 2017 hormone therapy position statement of The North American Menopause Society</p><p>1.11.5.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/26872610/"" target=""_blank"">Baber et al., Climacteric. 2016 Apr;19(2):109-50 </a>\xa02016 IMS Recommendations on women’s midlife health and menopause hormone therapy</p><p>1.11.6.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/29583019/"" target=""_blank"">Warren., Climacteric. 2018 Aug;21(4):355-357</a> Vaginal progesterone and the vaginal first-pass effect</p><p>1.11.7.<span style=""font-size: 7pt;""> </span>\xa0<a href=""https://pubmed.ncbi.nlm.nih.gov/29630427/"" target=""_blank"">Mirkin., Climacteric. 2018 Aug;21(4):346-354</a> Evidence on the use of progesterone in menopausal hormone therapy</p><p>1.11.8.<span style=""font-size: 7pt;""> </span><a href=""https://www.imsociety.org/2021/02/25/progestogen-progestin-progesterone-why-all-the-confusion-webinar/"" target=""_blank"">International Menopause Society Webinar. March 23 2021</a>; Progestogens, progestin, progesterone. Why all the confusion? IMS online education module. </p><p>1.11.9.<span style=""font-size: 7pt;""> </span><a href=""https://pubmed.ncbi.nlm.nih.gov/22432812/"" target=""_blank"">\xa0Gompel., Climacteric. 2012 Apr;15 Suppl 1:18-25</a>. Micronized progesterone and its impact on the endometrium and breast vs. progestogens</p><p>1.11.10.<span style=""font-size: 7pt;"">\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24223752/"" target=""_blank"">Cordina-Duverger et al., PLoS One. 2013 Nov 1;8(11):e78016</a> Risk of Breast Cancer by Type of Menopausal Hormone Therapy: A Case-Control Study among Post-Menopausal Women in France</p><p><br></p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee noted that micronised progesterone has improved bioavailability compared with currently funded MHT options and can be administered vaginally for those women with side-effects related to systemic use. The Subcommittee also noted that micronised progesterone does not have the adverse interactions with glucocorticoid or androgen receptors that lead to weight gain, bloating, and skin problems which are experienced with the currently funded options. The Subcommittee noted that the median duration of use of micronised progesterone or MHT would be approximately 5 years for most women, and that the majority of patients would likely cease treatment once their severe menopause symptoms subside. </p><p><br></p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, for managing menopausal symptoms, approximately 10% of women at menopause would use MHT and that the numbers of patients prescribed MHT likely includes patients treated for other indications (noting the majority of funded MHT products are not subject to funding restrictions). The Subcommittee considered that this would equate to approximately 25,000 women in New Zealand annually. The Subcommittee considered that if micronised progesterone were to be open listed there would be uptake from a younger age group who are at a higher clotting and stroke risk and for whom currently funded options are not appropriate, such as those who have gone through premature menopause or have hypogonadism. The Subcommittee considered the potential increased usage from indications other than those previously noted would be minimal.</p><p><br></p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the cost associated with open listing micronised progesterone would be minimal, especially when taking into consideration the decrease in breast cancer risk, and that any future economic analysis should include the increased risk in breast cancer for comparator agents.\xa0</p>', 'Status_History__c': 'a132P000000D5bQQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended </b>that micronised progesterone be listed with a <b>high priority</b>, and with restrictions removed.</p><p><span style=""font-size: 10pt; font-family: Arial, sans-serif;"">1.2. In making this recommendation, the Committee considered the lack of alternative treatments for patients who cannot tolerate currently funded options, the increased risk of breast cancer associated with currently funded options, the health need of women relating to a universal age-related change, and the health need of Māori and Pacific women who are at an increased risk of early menopause. The Committee also considered the unmet health need from low uptake of menopause hormone therapy, as a result of the breast cancer concerns about the currently funded menopause hormone therapy options.</span></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended </b>that micronised progesterone be listed with a <b>high priority</b>, and with restrictions removed.</p><p><span style=""font-size: 10pt; font-family: Arial, sans-serif;"">1.2. In making this recommendation, the Committee considered the lack of alternative treatments for patients who cannot tolerate currently funded options, the increased risk of breast cancer associated with currently funded options, the health need of women relating to a universal age-related change, and the health need of Māori and Pacific women who are at an increased risk of early menopause. The Committee also considered the unmet health need from low uptake of menopause hormone therapy, as a result of the breast cancer concerns about the currently funded menopause hormone therapy options.</span></p>', 'change': None}, 'Published_Discussion': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that menopause is the natural cessation of a woman’s menstrual cycle and marks the end of fertility and occurs when a woman has not menstruated in 12 consecutive months and can no longer become pregnant naturally. The Committee also noted that menopause can cause uncomfortable and/or debilitating symptoms, such as hot flushes, night sweats, weight gain, and mood fluctuations and that every woman’s menopause experience is unique. The Committee noted that menopause is usually age-related as part of a woman’s natural life course (unless premature for disease or disease treatment-related reasons) and that menopause symptoms begin in the few years before menopause and can continue for four or more years after menopause.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that the average age of natural menopause for New Zealand women is stated to be 52 years but can occur anytime between the ages of 45 and 55 years and that the estimated number of women in this age range in New Zealand is approximately 230,000. The Committee noted that 5 -10% of women in the menopausal age range would be taking menopause hormone therapy (MHT).</p><p>1.3.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that menopause affects women universally, and given the sometimes debilitating nature of its symptoms, any issues with access to effective treatments was a differential gender-based access inequity.\xa0</p><p>1.4.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that micronised progesterone for menopause has been considered multiple times since 2012 by both PTAC and the Endocrinology Subcommittee as follows:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2012-05-29.pdf"" target=""_blank"">May 2012</a> the Endocrinology Subcommittee was supportive of a listing of micronised progesterone, noting it was the preferred progesterone option</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2012-05-29.pdf"" target=""_blank"">August 2012</a> PTAC recommended the application be declined</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf"" target=""_blank"">June 2014</a> the Endocrinology Subcommittee requested that PTAC reconsider its recommendation to decline</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">November 2014</a> PTAC accepted the Subcommittees recommendation for re-review in, given new evidence could be presented</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2016-02-update-2.pdf"" target=""_blank"">February 2016</a> PTAC again recommended the application be declined</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2016-06.pdf"" target=""_blank"">June 2016</a> the Endocrinology Subcommittee again requested PTAC reconsider their previous recommendation</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2016-11.pdf"" target=""_blank"">November 2016</a> PTAC again reviewed micronised progesterone, where it noted that the only evidence that PTAC had not seen previously cited by the Endocrinology Subcommittee (<a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2016-06.pdf"" target=""_blank"">June 2016</a>) was the Dartois et al. (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Int J Cancer 2016;138:2415-27</a>) study, and PTAC requested that this be presented at a future PTAC meeting</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">March 2021</a> the Endocrinology Subcommittee assessed this application, recommending that access to micronised progesterone for menopause hormone therapy be widened by removing the funding restrictions, with a high priority within the context of treatment of endocrine disease.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that progesterone in combination with oestrogen is used to treat the symptoms of menopause, and that there are significant health risks in women in with an intact uterus if oestrogen is used unopposed, particularly the increased risk of endometrial cancer. The Committee noted that oestrogen is usually combined with a synthetic form of progesterone, which is associated with its own risks, namely an increase in thromboembolic events and breast cancer.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that the product being considered for this application is a natural micronised progesterone derived from yams which has all the properties of endogenous progesterone, in particular gestagenic, antiestrogenic, slightly anti-androgenic and anti-aldosterone effects. The Committee noted that micronised progesterone is Medsafe approved and is indicated for adjunctive use with an oestrogen in postmenopausal women with an intact uterus for hormone replacement therapy and that the usual dose is 200 mg per day at bedtime at least 12 to 14 days per month, i.e. on days 15 to 26 of each cycle or in the last 2 weeks of each treatment sequence of oestrogen therapy followed by approximately one week without any replacement therapy.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that at its 2021 meeting, the Endocrinology Subcommittee considered that micronised progesterone lowers an individual’s risk of breast cancer cardiovascular disease, mood fluctuation, stroke, and clotting, compared to currently funded synthetic alternatives. The Committee noted that evidence for the use of micronised progesterone comes primarily from the E3N cohort study of 98,995 women initiated in France in 1990 to investigate the risk factors associated with cancer and other non-communicable diseases (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Dartois et al. Int J Cancer 2016;138:2415-27</a>).</p><p>The Committee noted that the Dartois et al. study reported post-menopausal breast cancer cases as follows; 108 cases in those taking oral oestrogens only (108/1747 participants; hazard ratio (HR) 1.07; 95% CI 0.92 to 1.23), 296 cases in those taking oral oestrogens with progesterone/dydrogesterone (296/4621 participants; HR 1.20; 95% CI 1.09 to 1.32), and 412 cases in those taking oral oestrogens with other progestogen (412/5253 participants; HR 1.72; 95% CI 1.57 to 1.88).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of a systematic review and meta-analysis comparing progesterone with synthetic progestins, each in combination with oestrogens, against the risk of breast cancer and cardiovascular events (<a href=""https://pubmed.ncbi.nlm.nih.gov/27456847/"" target=""_blank"">Asi et al. Syst Rev. 2016;5:121</a>). The Committee noted that this study did not include the Dartois et al. study, and that it reported that progesterone was associated with lower breast cancer risk compared with synthetic progestins when each is given in combination with oestrogen (relative risk 0.67; 95 % CI 0.55 to 0.81).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a systematic literature review on the impact of menopausal hormone therapy (MHT) containing micronised progesterone on the mammary gland (<a href=""https://pubmed.ncbi.nlm.nih.gov/29384406/"" target=""_blank"">Stute et al. Climacteric. 2018;21:111-22</a>). The Committee noted that the review included 19 studies, with multiple reports from the same authors, including relating to the E3N cohort. The Committee noted that the study reported no increased risk of breast cancer for up to five years with the use of micronised progesterone in combination with oestrogen. The Committee also noted, however, that micronised progesterone or dydrogesterone were associated with a slight but significant increase in breast cancer risk after an average of 6 years of treatment duration.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was made aware of a 2020 summary of evidence that stated that it appears that minimal oestrogen is required to initiate the biological processes that promote cancer development (<a href=""https://pubmed.ncbi.nlm.nih.gov/32329768/"" target=""_blank"">Khan S A. JAMA Netw Open. 2020;3:e203608</a>). The Committee considered that the progesterone effect in breast cancer incidence is minor, but that this depends on the type of cancer.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted the following evidence relating to the use of micronised progesterone in the management of menopause symptoms:</p><ul><li><a href=""https://pubmed.ncbi.nlm.nih.gov/27898258/"" target=""_blank"">Yang et al. Gynecol Endocrinol. 2017;33:87-92</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/29570359/"" target=""_blank"">Scarabin PY. Climacteric. 2018;21:341-45</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/22024394/"" target=""_blank"">Canonico et al. Maturitas. 2011 Dec;70:354-60</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/28898378/"" target=""_blank"">Manson et al. JAMA. 2017 Sep 12;318:927-38</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/27548404/"" target=""_blank"">Palacios et Mejía. Expert Opin Drug Saf. 2016 Nov;15:1515-25</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/28650869/"" target=""_blank"">The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. Menopause. 2017 Jul;24:728-53</a></li><li>Baber et al. Climacteric. 2016 Apr;19:109-50</li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/29583019/"" target=""_blank"">Warren. Climacteric. 2018 Aug;21:355-357</a></li><li><a href=""https://www.imsociety.org/2021/02/25/progestogen-progestin-progesterone-why-all-the-confusion-webinar/"" target=""_blank"">International Menopause Society Webinar. March 23 2021</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/22432812/"" target=""_blank"">Gompel. Climacteric. 2012 Apr;15 Suppl 1:18-25</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/24223752/"" target=""_blank"">Cordina-Duverger et al. PLoS One. 2013 Nov 1;8:e78016</a></li><li><a href=""https://journals.lww.com/menopausejournal/Abstract/2017/07000/The_2017_hormone_therapy_position_statement_of_The.5.aspx"" target=""_blank"">The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. Menopause. 2017;24:728-53</a></li></ul><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence suggests that the risk of venous thromboembolism increases by about one half with synthetic progesterone, and that synthetic progesterone has an androgenic effect which increases cardiovascular risk. The Committee noted that micronised progesterone does not have this androgenic activity and thus might be expected to not increase cardiovascular risk. The Committee also noted that in France studies have been published widely on the use of micronised progesterone reducing side effects such as bloating, mood swings, depression and acne. The Committee noted that the increased risk of breast cancer from existing MHT treatments persists for more than 10 years following discontinuation of treatment, and that those women who used MHT for 10 years had double the chance of developing breast cancer than those who used it for only 5 years (<a href=""https://pubmed.ncbi.nlm.nih.gov/31474332/"" target=""_blank"">Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 2019;394:1159-68</a>).</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that risks relating to endometrial cancer were not discussed at the 2021 Endocrinology Subcommittee meeting. The Committee noted a publication investigating the risk of endometrial cancer associated with different hormone replacement therapies in the E3N cohort (<a href=""https://pubmed.ncbi.nlm.nih.gov/25008104/"" target=""_blank"">Fournier et al. Am J Epidemiol. 2014;180:508-17</a>). The Committee noted that 301 endometrial cancers were reported in total, and that the use of micronised progesterone with oestrogen increased the risk of endometrial cancer compared with those who had never used MHT (hazard ratio 1.80; 95% CI 1.38 to 2.34). The Committee also noted that the risk increased with prolonged use; those using micronised progesterone for less than five years had a hazard ratio of 1.30, which increased to 2.66 with use spanning longer than 5 years. The Committee noted, however, that the dose of micronised progesterone in the study was unclear and that many of the patients used micronised progesterone as a vaginal gel. The Committee considered that the dose of micronised progesterone may not have been high enough to mitigate the effect of oestrogen in inducing endometrial cancer.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was made aware of a 3-year multicentre, randomized, double-masked, placebo-controlled trial investigating the risk of endometrial hyperplasia in 596 postmenopausal women aged 45 through 64 years without contraindication to hormone therapy who were randomised to receive either placebo, conjugated equine oestrogens, conjugated equine oestrogens with medroxyprogesterone acetate, or conjugated equine oestrogens with micronised progesterone (<a href=""https://pubmed.ncbi.nlm.nih.gov/8569016/"" target=""_blank"">Judd et al. JAMA. 1996;275:370-5</a>). The Committee noted that patients receiving oestrogens in combination with progesterone did not have an increased rates of endometrial hyperplasia compared to placebo (P=0.16). The Committee considered that pharmacoepidemiology studies are a more reliable source of information regarding development of rare adverse events over time than randomised controlled trials.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee were made aware of a study investigating the association of various types of hormone therapies with the risk of endometrial cancer among postmenopausal women recruited into the European Prospective Investigation into Cancer and Nutrition between 1992 and 2000 (<a href=""https://pubmed.ncbi.nlm.nih.gov/20961969/"" target=""_blank"">Allen et al. Am J Epidemiol. 2010:172:1394-403</a>). The Committee noted that of 115,474 women in the study, 601 developed endometrial cancer, and that 81% of these cases were verified. The Committee noted that the hazard ratio associated with micronised progesterone was 2.42, compared with 1.73 with synthetic progesterone (95% CIs 1.53 to 3.38 and 0.84 to 1.97, respectively). The Committee considered that this study had a low risk of selection bias, a moderate risk detection bias, high internal validity, and was of moderate quality.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of progesterone and endometrial cancer which included 11 randomised controlled trials and 14 observational studies (<a href=""https://pubmed.ncbi.nlm.nih.gov/27451318/"" target=""_blank"">Sjögren et al. Maturitas. 2016;91:25-35</a>). The Committee noted that micronised progesterone increased the risk of endometrial cancer, especially when used continuously (former use of micronised progesterone was associated with a hazard ratio of 1.44 [95% CI 0.99 to 2.08] compared with 2.42 with ‘current use’ [95% CI 1.53 to 3.83]). The Committee noted that other types of progesterone did not seem to affect the risk of endometrial cancer.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of MHT and the risk of endometrial cancer that included 31 papers, only two of which were randomised controlled trials, and also included the Sjogren et al. and Allen et al. papers (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465414/pdf/cancers-12-02195.pdf"" target=""_blank"">Tempfer et al. Cancers (Basel). 2020;12:2195</a>). The Committee noted that short term use of micronised progesterone (5 years or less) was not associated with an increased risk of endometrial cancer. The Committee noted that the randomised controlled trials in this review did not adjust for confounders and were of low precision, and that some of the studies included were funded by drug manufacturers. The Committee also noted that very few studies excluded the possibility of cancer hyperplasia at enrolment, and that the majority of participants in the studies self-reported exposure to the study drugs, which carries the risk of detection and recall bias. The Committee considered that studies with a single baseline exposure categorisation carry a classification bias, as some women may have used different hormone formulations.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was made aware of a study investigating the ethnic-specific trends in endometrial cancer across different age groups in New Zealand (<a href=""https://pubmed.ncbi.nlm.nih.gov/30671687/"" target=""_blank"">Scott et al. Cancer Causes Control. 2019;30:121-27).</a> The Committee noted that there has been a gradual increase in endometrial cancer registrations in New Zealand since 1996, and that Pacific women have the highest registered incidence.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that body mass index (BMI) is a strong indicator of endometrial cancer risk and that the association is no longer clear among users of MHT (<a href=""https://pubmed.ncbi.nlm.nih.gov/18187388/"" target=""_blank"">McCullough et al. Cancer Epidemiol Biomarkers Prev. 2008;17:73-9</a>). The Committee noted that use of MHT has been associated a reduced risk of endometrial cancer due to being high BMI/obesity, and that this association does not differ between continuous and sequential therapy (<a href=""https://pubmed.ncbi.nlm.nih.gov/21030602/"" target=""_blank"">Crosbie et al. Cancer Epidemiol Biomarkers Prev. 2010;19:3119-30</a>). The Committee also noted that in a large US cohort study that those with a BMI of over 30 had a relative risk of developing endometrial cancer of 5.41 compared to those with a BMI under 25 in those who had never used MHT, compared to a relative risk of 2.35 amongst those who had formerly used MHT (<a href=""https://pubmed.ncbi.nlm.nih.gov/17416763/"" target=""_blank"">Chang et al. Cancer Epidemiol Biomarkers Prev. 2007;16:723-30</a>). The Committee noted that progestagens are considered to potentially counteract the adverse effect of oestrogens on the endometrium,\xa0that association between progestagen use and endometrial cancer risk being greater the more days every month that progestagens are added to oestrogen and the more obese that users are (<a href=""https://pubmed.ncbi.nlm.nih.gov/15866308/"" target=""_blank"">Beral et al. Lancet. 2005;365:1543-51</a>).</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence suggests that currently funded MHTs carry an increased risk of breast cancer, though the evidence is mixed, and that the effect of MHT on breast cancer is likely to differ according to the type of breast cancer. The Committee considered that if there is an increased risk of breast cancer, that it is likely the risk increases with duration of treatment and persists after discontinuing treatment. The Committee considered that micronised progesterone may also carry an increased risk of breast cancer (compared to non-users of MHT) but the extent of this increased risk was marginal, and micronised progesterone was probably associated with lower risks when compared with synthetic progesterone. However, the Committee considered the lack of published evidence reporting mortality benefits of micronised progesterone limited conclusions about differences in breast cancer risk.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that overall, micronised progesterone carries an increased risk of endometrial cancer and breast cancer, although the breast cancer risk associated with micronised progesterone is lower than with other MHT therapies. The Committee noted that breast cancer incidence in New Zealand is much higher than endometrial cancer, and considered that any decrease in breast cancer incidence would be beneficial for patients and the health system and thus any relative reduction in breast cancer incidence would outweigh a potential increase in endometrial cancer. The Committee considered that there was no evidence to indicate if the increased risk of endometrial cancer persists beyond treatment discontinuation. The Committee considered that the increased endometrial cancer risk may also be manageable in many cases if patients present with low grade endometrial cancer, as this can be resolved through withdrawal of the agent.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that while there was uncertainty in the magnitude of difference in breast cancer risk between agents, it was likely that micronised progesterone may be associated with an improved side effect profile vs synthetic progesterone. The Committee considered that it was unlikely micronised progesterone was superior with regard to mood fluctuations vs currently funded MHTs.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a recent UK study which reported 14 million workdays lost annually by women suffering from symptoms of menopause, and that 25% of women going through menopause consider leaving work due to their symptoms (<a href=""https://www.burnesspaull.com/__data/assets/pdf_file/0019/13159/Menopause-in-the-Workplace_print.pdf"" target=""_blank"">Burness Paul report: Menopause in the Workplace. 2019</a>). The Committee considered that it is important to have options for patients who cannot tolerate the currently available funded options.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if micronised progesterone were to be funded for this indication nearly half of women would switch to this from synthetic progesterone, and that women who do not take MHT due to the breast cancer risk, may be more likely to start treatment if micronised progesterone were available. The Committee also considered that it is likely that all women initiating MHT would start on micronised progesterone. The Committee noted that uptake of MHT in the Māori and Pacific community is low and considered that a different treatment option may increase use in these communities. The Committee noted, however, that the reason for the decreased up take in these communities is likely attributable to a variety of factors, including perceived safety concerns, intolerance issues and access inequities, and that the lower uptake is unlikely to be purely a function of insufficient treatment options. The Committee considered that uptake may also be higher than predicted due to micronised progesterone being ‘natural’ and the perceived and actual benefits of this over synthetic progesterone.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that MHT uptake has been reducing over time, and this may be due to the perceived safety concerns around MHT treatment. The Committee considered that funding a new option that is not perceived to carry the same risks of breast cancer could help improve uptake of MHT. The Committee considered that improved uptake of MHT would improve quality of life and may be associated with fewer women having severe symptoms that force them to stop paid work.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the number of additional women who may access MHT (and are not currently receiving MHT) if micronised progesterone were funded is uncertain. The Committee noted that uptake of MHT is much lower in New Zealand compared to overseas and considered that attitudes towards MHT are significantly different overseas and thus difficult to compare to New Zealand. The Committee estimated that it may be reasonable to assume an increase in the number of MHT-treated patients of up to 20% and considered that there is unlikely to be a large pool of patients not receiving treatment who will switch to micronised progesterone.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that micronised progesterone is currently listed for the prevention of pre-term labour, and that it is also used in other countries for amenorrhoea and assisted reproductive technology. The Committee considered that if micronised progesterone were to be open listed that it would be used more widely for indications other than MHT for menopause, but that the increase in uptake from these other groups could not be predicted accurately. The Committee considered that the usage in these other indications would likely be small in comparison to the usage in managing menopausal symptoms.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the below table summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for micronised progesterone if it were to be funded in New Zealand for menopause. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><table class=""ql-table-blob"" border=""0"" style=""width: 460.45pt;"" width=""614""><tbody><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal"" style=""""><b>P</b><span style=""color: black;"">opulation </span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style="""">Menopausal patients requiring\n  menopause hormone therapy (MHT)</p><p class=""MsoNormal"" style="""">A small number of patients\n  accessing micronised progesterone for other indications if listed without\n  restriction</p></td></tr><tr style=""height: 81.15pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 81.15pt;"" width=""100""><p class=""MsoNormal"" style=""""><b><span style=""color: black;"">I</span></b><span style=""color: black;"">ntervention</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 81.15pt;"" width=""514""><p class=""MsoNormal"" style="""">Micronised progesterone, dosing\n  either:</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>100mg/day\n  on days 1-25 each month, or</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>200mg/day\n  on days 15-26 each month</p><p class=""MsoNormal"" style="""">\xa0</p><p class=""MsoNormal"" style="""">Mean duration of use 4.2 years, with\n  ~44% requiring &gt;5 years of treatment (<a href=""https://academic.oup.com/aje/article/180/5/508/2739102?login=true"" target=""_blank"">Fournier et al. Am J Epidemiol\n  2014;180: 508-17</a>)<i><span style=""font-size: 11.0pt;""></span></i></p></td></tr><tr style=""height: 49.0pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 49.0pt;"" width=""100""><p class=""MsoNormal"" style=""""><b><span style=""color: black;"">C</span></b><span style=""color: black;"">omparator(s)</span></p><p class=""MsoNormal"" style=""""><span style=""color: black;"">(NZ context)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 49.0pt;"" width=""514""><p class=""MsoNormal"" style="""">Currently funded MHTs; most\n  commonly prescribed include medroxyprogesterone acetate, oestradiol with\n  norethisterone (which is partially funded), oestradiol valerate and\n  ethinyloestradiol</p></td></tr><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal"" style=""""><b><span style=""color: black;"">O</span></b><span style=""color: black;"">utcome(s)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Improved\n  quality of life compared to patients on no treatment</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Efficacy\n  similar to other MHTs in managing menopausal symptoms</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Improved\n  side effect profile vs currently funded MHTs</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Marginally\n  lower<i> </i>risk of breast cancer compared with currently funded MHTs</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Marginally\n  higher risk of breast cancer compared with no treatment, for those patients\n  on treatment for &gt;5 years (<a href=""https://link.springer.com/article/10.1007/s10549-014-2934-6"" target=""_blank"">Fournier\n  et al. Breast Cancer Res Treat 2014;145: 535-43</a>)</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Higher\n  risk of endometrial cancer vs no treatment and vs currently funded MHTs (<a href=""https://academic.oup.com/aje/article/180/5/508/2739102?login=true"" target=""_blank"">Fournier et al. 2014</a>)</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Lower\n  risk of VTEs vs currently funded MHTs (<a href=""https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/412423"" target=""_blank"">Huerta et al. Arch Intern 2007;167: 935-43</a>)</p></td></tr><tr style=""height: 22.1pt;""><td colspan=""2"" rowspan=""1"" valign=""top"" style=""width: 460.45pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""614""><p class=""MsoNormal"" style=""""><span style=""font-size: 9.0pt;"">Table definitions: Population,\n  the target population for the pharmaceutical; Intervention, details of the\n  intervention pharmaceutical; Comparator, details the therapy(s) that the\n  patient population would receive currently (status quo – including best supportive\n  care); Outcomes, details the key therapeutic outcome(s) and source of outcome\n  data.\xa0 </span></p></td></tr></tbody></table><p><br></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that menopause is the natural cessation of a woman’s menstrual cycle and marks the end of fertility and occurs when a woman has not menstruated in 12 consecutive months and can no longer become pregnant naturally. The Committee also noted that menopause can cause uncomfortable and/or debilitating symptoms, such as hot flushes, night sweats, weight gain, and mood fluctuations and that every woman’s menopause experience is unique. The Committee noted that menopause is usually age-related as part of a woman’s natural life course (unless premature for disease or disease treatment-related reasons) and that menopause symptoms begin in the few years before menopause and can continue for four or more years after menopause.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that the average age of natural menopause for New Zealand women is stated to be 52 years but can occur anytime between the ages of 45 and 55 years and that the estimated number of women in this age range in New Zealand is approximately 230,000. The Committee noted that 5 -10% of women in the menopausal age range would be taking menopause hormone therapy (MHT).</p><p>1.3.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that menopause affects women universally, and given the sometimes debilitating nature of its symptoms, any issues with access to effective treatments was a differential gender-based access inequity.\xa0</p><p>1.4.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that micronised progesterone for menopause has been considered multiple times since 2012 by both PTAC and the Endocrinology Subcommittee as follows:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2012-05-29.pdf"" target=""_blank"">May 2012</a> the Endocrinology Subcommittee was supportive of a listing of micronised progesterone, noting it was the preferred progesterone option</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2012-05-29.pdf"" target=""_blank"">August 2012</a> PTAC recommended the application be declined</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf"" target=""_blank"">June 2014</a> the Endocrinology Subcommittee requested that PTAC reconsider its recommendation to decline</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">November 2014</a> PTAC accepted the Subcommittees recommendation for re-review in, given new evidence could be presented</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2016-02-update-2.pdf"" target=""_blank"">February 2016</a> PTAC again recommended the application be declined</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2016-06.pdf"" target=""_blank"">June 2016</a> the Endocrinology Subcommittee again requested PTAC reconsider their previous recommendation</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2016-11.pdf"" target=""_blank"">November 2016</a> PTAC again reviewed micronised progesterone, where it noted that the only evidence that PTAC had not seen previously cited by the Endocrinology Subcommittee (<a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2016-06.pdf"" target=""_blank"">June 2016</a>) was the Dartois et al. (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Int J Cancer 2016;138:2415-27</a>) study, and PTAC requested that this be presented at a future PTAC meeting</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">March 2021</a> the Endocrinology Subcommittee assessed this application, recommending that access to micronised progesterone for menopause hormone therapy be widened by removing the funding restrictions, with a high priority within the context of treatment of endocrine disease.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that progesterone in combination with oestrogen is used to treat the symptoms of menopause, and that there are significant health risks in women in with an intact uterus if oestrogen is used unopposed, particularly the increased risk of endometrial cancer. The Committee noted that oestrogen is usually combined with a synthetic form of progesterone, which is associated with its own risks, namely an increase in thromboembolic events and breast cancer.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that the product being considered for this application is a natural micronised progesterone derived from yams which has all the properties of endogenous progesterone, in particular gestagenic, antiestrogenic, slightly anti-androgenic and anti-aldosterone effects. The Committee noted that micronised progesterone is Medsafe approved and is indicated for adjunctive use with an oestrogen in postmenopausal women with an intact uterus for hormone replacement therapy and that the usual dose is 200 mg per day at bedtime at least 12 to 14 days per month, i.e. on days 15 to 26 of each cycle or in the last 2 weeks of each treatment sequence of oestrogen therapy followed by approximately one week without any replacement therapy.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that at its 2021 meeting, the Endocrinology Subcommittee considered that micronised progesterone lowers an individual’s risk of breast cancer cardiovascular disease, mood fluctuation, stroke, and clotting, compared to currently funded synthetic alternatives. The Committee noted that evidence for the use of micronised progesterone comes primarily from the E3N cohort study of 98,995 women initiated in France in 1990 to investigate the risk factors associated with cancer and other non-communicable diseases (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Dartois et al. Int J Cancer 2016;138:2415-27</a>).</p><p>The Committee noted that the Dartois et al. study reported post-menopausal breast cancer cases as follows; 108 cases in those taking oral oestrogens only (108/1747 participants; hazard ratio (HR) 1.07; 95% CI 0.92 to 1.23), 296 cases in those taking oral oestrogens with progesterone/dydrogesterone (296/4621 participants; HR 1.20; 95% CI 1.09 to 1.32), and 412 cases in those taking oral oestrogens with other progestogen (412/5253 participants; HR 1.72; 95% CI 1.57 to 1.88).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of a systematic review and meta-analysis comparing progesterone with synthetic progestins, each in combination with oestrogens, against the risk of breast cancer and cardiovascular events (<a href=""https://pubmed.ncbi.nlm.nih.gov/27456847/"" target=""_blank"">Asi et al. Syst Rev. 2016;5:121</a>). The Committee noted that this study did not include the Dartois et al. study, and that it reported that progesterone was associated with lower breast cancer risk compared with synthetic progestins when each is given in combination with oestrogen (relative risk 0.67; 95 % CI 0.55 to 0.81).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a systematic literature review on the impact of menopausal hormone therapy (MHT) containing micronised progesterone on the mammary gland (<a href=""https://pubmed.ncbi.nlm.nih.gov/29384406/"" target=""_blank"">Stute et al. Climacteric. 2018;21:111-22</a>). The Committee noted that the review included 19 studies, with multiple reports from the same authors, including relating to the E3N cohort. The Committee noted that the study reported no increased risk of breast cancer for up to five years with the use of micronised progesterone in combination with oestrogen. The Committee also noted, however, that micronised progesterone or dydrogesterone were associated with a slight but significant increase in breast cancer risk after an average of 6 years of treatment duration.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was made aware of a 2020 summary of evidence that stated that it appears that minimal oestrogen is required to initiate the biological processes that promote cancer development (<a href=""https://pubmed.ncbi.nlm.nih.gov/32329768/"" target=""_blank"">Khan S A. JAMA Netw Open. 2020;3:e203608</a>). The Committee considered that the progesterone effect in breast cancer incidence is minor, but that this depends on the type of cancer.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted the following evidence relating to the use of micronised progesterone in the management of menopause symptoms:</p><ul><li><a href=""https://pubmed.ncbi.nlm.nih.gov/27898258/"" target=""_blank"">Yang et al. Gynecol Endocrinol. 2017;33:87-92</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/29570359/"" target=""_blank"">Scarabin PY. Climacteric. 2018;21:341-45</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/22024394/"" target=""_blank"">Canonico et al. Maturitas. 2011 Dec;70:354-60</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/28898378/"" target=""_blank"">Manson et al. JAMA. 2017 Sep 12;318:927-38</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/27548404/"" target=""_blank"">Palacios et Mejía. Expert Opin Drug Saf. 2016 Nov;15:1515-25</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/28650869/"" target=""_blank"">The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. Menopause. 2017 Jul;24:728-53</a></li><li>Baber et al. Climacteric. 2016 Apr;19:109-50</li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/29583019/"" target=""_blank"">Warren. Climacteric. 2018 Aug;21:355-357</a></li><li><a href=""https://www.imsociety.org/2021/02/25/progestogen-progestin-progesterone-why-all-the-confusion-webinar/"" target=""_blank"">International Menopause Society Webinar. March 23 2021</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/22432812/"" target=""_blank"">Gompel. Climacteric. 2012 Apr;15 Suppl 1:18-25</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/24223752/"" target=""_blank"">Cordina-Duverger et al. PLoS One. 2013 Nov 1;8:e78016</a></li><li><a href=""https://journals.lww.com/menopausejournal/Abstract/2017/07000/The_2017_hormone_therapy_position_statement_of_The.5.aspx"" target=""_blank"">The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. Menopause. 2017;24:728-53</a></li></ul><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence suggests that the risk of venous thromboembolism increases by about one half with synthetic progesterone, and that synthetic progesterone has an androgenic effect which increases cardiovascular risk. The Committee noted that micronised progesterone does not have this androgenic activity and thus might be expected to not increase cardiovascular risk. The Committee also noted that in France studies have been published widely on the use of micronised progesterone reducing side effects such as bloating, mood swings, depression and acne. The Committee noted that the increased risk of breast cancer from existing MHT treatments persists for more than 10 years following discontinuation of treatment, and that those women who used MHT for 10 years had double the chance of developing breast cancer than those who used it for only 5 years (<a href=""https://pubmed.ncbi.nlm.nih.gov/31474332/"" target=""_blank"">Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 2019;394:1159-68</a>).</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that risks relating to endometrial cancer were not discussed at the 2021 Endocrinology Subcommittee meeting. The Committee noted a publication investigating the risk of endometrial cancer associated with different hormone replacement therapies in the E3N cohort (<a href=""https://pubmed.ncbi.nlm.nih.gov/25008104/"" target=""_blank"">Fournier et al. Am J Epidemiol. 2014;180:508-17</a>). The Committee noted that 301 endometrial cancers were reported in total, and that the use of micronised progesterone with oestrogen increased the risk of endometrial cancer compared with those who had never used MHT (hazard ratio 1.80; 95% CI 1.38 to 2.34). The Committee also noted that the risk increased with prolonged use; those using micronised progesterone for less than five years had a hazard ratio of 1.30, which increased to 2.66 with use spanning longer than 5 years. The Committee noted, however, that the dose of micronised progesterone in the study was unclear and that many of the patients used micronised progesterone as a vaginal gel. The Committee considered that the dose of micronised progesterone may not have been high enough to mitigate the effect of oestrogen in inducing endometrial cancer.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was made aware of a 3-year multicentre, randomized, double-masked, placebo-controlled trial investigating the risk of endometrial hyperplasia in 596 postmenopausal women aged 45 through 64 years without contraindication to hormone therapy who were randomised to receive either placebo, conjugated equine oestrogens, conjugated equine oestrogens with medroxyprogesterone acetate, or conjugated equine oestrogens with micronised progesterone (<a href=""https://pubmed.ncbi.nlm.nih.gov/8569016/"" target=""_blank"">Judd et al. JAMA. 1996;275:370-5</a>). The Committee noted that patients receiving oestrogens in combination with progesterone did not have an increased rates of endometrial hyperplasia compared to placebo (P=0.16). The Committee considered that pharmacoepidemiology studies are a more reliable source of information regarding development of rare adverse events over time than randomised controlled trials.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee were made aware of a study investigating the association of various types of hormone therapies with the risk of endometrial cancer among postmenopausal women recruited into the European Prospective Investigation into Cancer and Nutrition between 1992 and 2000 (<a href=""https://pubmed.ncbi.nlm.nih.gov/20961969/"" target=""_blank"">Allen et al. Am J Epidemiol. 2010:172:1394-403</a>). The Committee noted that of 115,474 women in the study, 601 developed endometrial cancer, and that 81% of these cases were verified. The Committee noted that the hazard ratio associated with micronised progesterone was 2.42, compared with 1.73 with synthetic progesterone (95% CIs 1.53 to 3.38 and 0.84 to 1.97, respectively). The Committee considered that this study had a low risk of selection bias, a moderate risk detection bias, high internal validity, and was of moderate quality.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of progesterone and endometrial cancer which included 11 randomised controlled trials and 14 observational studies (<a href=""https://pubmed.ncbi.nlm.nih.gov/27451318/"" target=""_blank"">Sjögren et al. Maturitas. 2016;91:25-35</a>). The Committee noted that micronised progesterone increased the risk of endometrial cancer, especially when used continuously (former use of micronised progesterone was associated with a hazard ratio of 1.44 [95% CI 0.99 to 2.08] compared with 2.42 with ‘current use’ [95% CI 1.53 to 3.83]). The Committee noted that other types of progesterone did not seem to affect the risk of endometrial cancer.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of MHT and the risk of endometrial cancer that included 31 papers, only two of which were randomised controlled trials, and also included the Sjogren et al. and Allen et al. papers (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465414/pdf/cancers-12-02195.pdf"" target=""_blank"">Tempfer et al. Cancers (Basel). 2020;12:2195</a>). The Committee noted that short term use of micronised progesterone (5 years or less) was not associated with an increased risk of endometrial cancer. The Committee noted that the randomised controlled trials in this review did not adjust for confounders and were of low precision, and that some of the studies included were funded by drug manufacturers. The Committee also noted that very few studies excluded the possibility of cancer hyperplasia at enrolment, and that the majority of participants in the studies self-reported exposure to the study drugs, which carries the risk of detection and recall bias. The Committee considered that studies with a single baseline exposure categorisation carry a classification bias, as some women may have used different hormone formulations.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was made aware of a study investigating the ethnic-specific trends in endometrial cancer across different age groups in New Zealand (<a href=""https://pubmed.ncbi.nlm.nih.gov/30671687/"" target=""_blank"">Scott et al. Cancer Causes Control. 2019;30:121-27).</a> The Committee noted that there has been a gradual increase in endometrial cancer registrations in New Zealand since 1996, and that Pacific women have the highest registered incidence.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that body mass index (BMI) is a strong indicator of endometrial cancer risk and that the association is no longer clear among users of MHT (<a href=""https://pubmed.ncbi.nlm.nih.gov/18187388/"" target=""_blank"">McCullough et al. Cancer Epidemiol Biomarkers Prev. 2008;17:73-9</a>). The Committee noted that use of MHT has been associated a reduced risk of endometrial cancer due to being high BMI/obesity, and that this association does not differ between continuous and sequential therapy (<a href=""https://pubmed.ncbi.nlm.nih.gov/21030602/"" target=""_blank"">Crosbie et al. Cancer Epidemiol Biomarkers Prev. 2010;19:3119-30</a>). The Committee also noted that in a large US cohort study that those with a BMI of over 30 had a relative risk of developing endometrial cancer of 5.41 compared to those with a BMI under 25 in those who had never used MHT, compared to a relative risk of 2.35 amongst those who had formerly used MHT (<a href=""https://pubmed.ncbi.nlm.nih.gov/17416763/"" target=""_blank"">Chang et al. Cancer Epidemiol Biomarkers Prev. 2007;16:723-30</a>). The Committee noted that progestagens are considered to potentially counteract the adverse effect of oestrogens on the endometrium,\xa0that association between progestagen use and endometrial cancer risk being greater the more days every month that progestagens are added to oestrogen and the more obese that users are (<a href=""https://pubmed.ncbi.nlm.nih.gov/15866308/"" target=""_blank"">Beral et al. Lancet. 2005;365:1543-51</a>).</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence suggests that currently funded MHTs carry an increased risk of breast cancer, though the evidence is mixed, and that the effect of MHT on breast cancer is likely to differ according to the type of breast cancer. The Committee considered that if there is an increased risk of breast cancer, that it is likely the risk increases with duration of treatment and persists after discontinuing treatment. The Committee considered that micronised progesterone may also carry an increased risk of breast cancer (compared to non-users of MHT) but the extent of this increased risk was marginal, and micronised progesterone was probably associated with lower risks when compared with synthetic progesterone. However, the Committee considered the lack of published evidence reporting mortality benefits of micronised progesterone limited conclusions about differences in breast cancer risk.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that overall, micronised progesterone carries an increased risk of endometrial cancer and breast cancer, although the breast cancer risk associated with micronised progesterone is lower than with other MHT therapies. The Committee noted that breast cancer incidence in New Zealand is much higher than endometrial cancer, and considered that any decrease in breast cancer incidence would be beneficial for patients and the health system and thus any relative reduction in breast cancer incidence would outweigh a potential increase in endometrial cancer. The Committee considered that there was no evidence to indicate if the increased risk of endometrial cancer persists beyond treatment discontinuation. The Committee considered that the increased endometrial cancer risk may also be manageable in many cases if patients present with low grade endometrial cancer, as this can be resolved through withdrawal of the agent.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that while there was uncertainty in the magnitude of difference in breast cancer risk between agents, it was likely that micronised progesterone may be associated with an improved side effect profile vs synthetic progesterone. The Committee considered that it was unlikely micronised progesterone was superior with regard to mood fluctuations vs currently funded MHTs.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a recent UK study which reported 14 million workdays lost annually by women suffering from symptoms of menopause, and that 25% of women going through menopause consider leaving work due to their symptoms (<a href=""https://www.burnesspaull.com/__data/assets/pdf_file/0019/13159/Menopause-in-the-Workplace_print.pdf"" target=""_blank"">Burness Paul report: Menopause in the Workplace. 2019</a>). The Committee considered that it is important to have options for patients who cannot tolerate the currently available funded options.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if micronised progesterone were to be funded for this indication nearly half of women would switch to this from synthetic progesterone, and that women who do not take MHT due to the breast cancer risk, may be more likely to start treatment if micronised progesterone were available. The Committee also considered that it is likely that all women initiating MHT would start on micronised progesterone. The Committee noted that uptake of MHT in the Māori and Pacific community is low and considered that a different treatment option may increase use in these communities. The Committee noted, however, that the reason for the decreased up take in these communities is likely attributable to a variety of factors, including perceived safety concerns, intolerance issues and access inequities, and that the lower uptake is unlikely to be purely a function of insufficient treatment options. The Committee considered that uptake may also be higher than predicted due to micronised progesterone being ‘natural’ and the perceived and actual benefits of this over synthetic progesterone.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that MHT uptake has been reducing over time, and this may be due to the perceived safety concerns around MHT treatment. The Committee considered that funding a new option that is not perceived to carry the same risks of breast cancer could help improve uptake of MHT. The Committee considered that improved uptake of MHT would improve quality of life and may be associated with fewer women having severe symptoms that force them to stop paid work.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the number of additional women who may access MHT (and are not currently receiving MHT) if micronised progesterone were funded is uncertain. The Committee noted that uptake of MHT is much lower in New Zealand compared to overseas and considered that attitudes towards MHT are significantly different overseas and thus difficult to compare to New Zealand. The Committee estimated that it may be reasonable to assume an increase in the number of MHT-treated patients of up to 20% and considered that there is unlikely to be a large pool of patients not receiving treatment who will switch to micronised progesterone.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that micronised progesterone is currently listed for the prevention of pre-term labour, and that it is also used in other countries for amenorrhoea and assisted reproductive technology. The Committee considered that if micronised progesterone were to be open listed that it would be used more widely for indications other than MHT for menopause, but that the increase in uptake from these other groups could not be predicted accurately. The Committee considered that the usage in these other indications would likely be small in comparison to the usage in managing menopausal symptoms.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the below table summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for micronised progesterone if it were to be funded in New Zealand for menopause. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><table class=""ql-table-blob"" border=""0"" style=""width: 460.45pt;"" width=""614""><tbody><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal"" style=""""><b>P</b><span style=""color: black;"">opulation </span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style="""">Menopausal patients requiring\n  menopause hormone therapy (MHT)</p><p class=""MsoNormal"" style="""">A small number of patients\n  accessing micronised progesterone for other indications if listed without\n  restriction</p></td></tr><tr style=""height: 81.15pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 81.15pt;"" width=""100""><p class=""MsoNormal"" style=""""><b><span style=""color: black;"">I</span></b><span style=""color: black;"">ntervention</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 81.15pt;"" width=""514""><p class=""MsoNormal"" style="""">Micronised progesterone, dosing\n  either:</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>100mg/day\n  on days 1-25 each month, or</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>200mg/day\n  on days 15-26 each month</p><p class=""MsoNormal"" style="""">\xa0</p><p class=""MsoNormal"" style="""">Mean duration of use 4.2 years, with\n  ~44% requiring &gt;5 years of treatment (<a href=""https://academic.oup.com/aje/article/180/5/508/2739102?login=true"" target=""_blank"">Fournier et al. Am J Epidemiol\n  2014;180: 508-17</a>)<i><span style=""font-size: 11.0pt;""></span></i></p></td></tr><tr style=""height: 49.0pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 49.0pt;"" width=""100""><p class=""MsoNormal"" style=""""><b><span style=""color: black;"">C</span></b><span style=""color: black;"">omparator(s)</span></p><p class=""MsoNormal"" style=""""><span style=""color: black;"">(NZ context)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 49.0pt;"" width=""514""><p class=""MsoNormal"" style="""">Currently funded MHTs; most\n  commonly prescribed include medroxyprogesterone acetate, oestradiol with\n  norethisterone (which is partially funded), oestradiol valerate and\n  ethinyloestradiol</p></td></tr><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal"" style=""""><b><span style=""color: black;"">O</span></b><span style=""color: black;"">utcome(s)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Improved\n  quality of life compared to patients on no treatment</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Efficacy\n  similar to other MHTs in managing menopausal symptoms</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Improved\n  side effect profile vs currently funded MHTs</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Marginally\n  lower<i> </i>risk of breast cancer compared with currently funded MHTs</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Marginally\n  higher risk of breast cancer compared with no treatment, for those patients\n  on treatment for &gt;5 years (<a href=""https://link.springer.com/article/10.1007/s10549-014-2934-6"" target=""_blank"">Fournier\n  et al. Breast Cancer Res Treat 2014;145: 535-43</a>)</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Higher\n  risk of endometrial cancer vs no treatment and vs currently funded MHTs (<a href=""https://academic.oup.com/aje/article/180/5/508/2739102?login=true"" target=""_blank"">Fournier et al. 2014</a>)</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Lower\n  risk of VTEs vs currently funded MHTs (<a href=""https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/412423"" target=""_blank"">Huerta et al. Arch Intern 2007;167: 935-43</a>)</p></td></tr><tr style=""height: 22.1pt;""><td colspan=""2"" rowspan=""1"" valign=""top"" style=""width: 460.45pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""614""><p class=""MsoNormal"" style=""""><span style=""font-size: 9.0pt;"">Table definitions: Population,\n  the target population for the pharmaceutical; Intervention, details of the\n  intervention pharmaceutical; Comparator, details the therapy(s) that the\n  patient population would receive currently (status quo – including best supportive\n  care); Outcomes, details the key therapeutic outcome(s) and source of outcome\n  data.\xa0 </span></p></td></tr></tbody></table><p><br></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee reviewed the application for the use of micronised progesterone for menopause hormone therapy (previously referred to as hormone replacement therapy).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee reviewed the application for the use of micronised progesterone for menopause hormone therapy (previously referred to as hormone replacement therapy).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2021', 'fs': 'Nov 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 20 August 2021.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 20 August 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztf22AC'}, 'Id': 'a0POZ000002Ztf22AC', 'Event_Date__c': '2021-11-23', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 20 August 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Nov 2021', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended </b>that micronised progesterone be listed with a <b>high priority</b>, and with restrictions removed.</p><p><span style=""font-size: 10pt; font-family: Arial, sans-serif;"">1.2. In making this recommendation, the Committee considered the lack of alternative treatments for patients who cannot tolerate currently funded options, the increased risk of breast cancer associated with currently funded options, the health need of women relating to a universal age-related change, and the health need of Māori and Pacific women who are at an increased risk of early menopause. The Committee also considered the unmet health need from low uptake of menopause hormone therapy, as a result of the breast cancer concerns about the currently funded menopause hormone therapy options.</span></p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee reviewed the application for the use of micronised progesterone for menopause hormone therapy (previously referred to as hormone replacement therapy).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that menopause is the natural cessation of a woman’s menstrual cycle and marks the end of fertility and occurs when a woman has not menstruated in 12 consecutive months and can no longer become pregnant naturally. The Committee also noted that menopause can cause uncomfortable and/or debilitating symptoms, such as hot flushes, night sweats, weight gain, and mood fluctuations and that every woman’s menopause experience is unique. The Committee noted that menopause is usually age-related as part of a woman’s natural life course (unless premature for disease or disease treatment-related reasons) and that menopause symptoms begin in the few years before menopause and can continue for four or more years after menopause.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that the average age of natural menopause for New Zealand women is stated to be 52 years but can occur anytime between the ages of 45 and 55 years and that the estimated number of women in this age range in New Zealand is approximately 230,000. The Committee noted that 5 -10% of women in the menopausal age range would be taking menopause hormone therapy (MHT).</p><p>1.3.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that menopause affects women universally, and given the sometimes debilitating nature of its symptoms, any issues with access to effective treatments was a differential gender-based access inequity.\xa0</p><p>1.4.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that micronised progesterone for menopause has been considered multiple times since 2012 by both PTAC and the Endocrinology Subcommittee as follows:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2012-05-29.pdf"" target=""_blank"">May 2012</a> the Endocrinology Subcommittee was supportive of a listing of micronised progesterone, noting it was the preferred progesterone option</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2012-05-29.pdf"" target=""_blank"">August 2012</a> PTAC recommended the application be declined</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf"" target=""_blank"">June 2014</a> the Endocrinology Subcommittee requested that PTAC reconsider its recommendation to decline</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">November 2014</a> PTAC accepted the Subcommittees recommendation for re-review in, given new evidence could be presented</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2016-02-update-2.pdf"" target=""_blank"">February 2016</a> PTAC again recommended the application be declined</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2016-06.pdf"" target=""_blank"">June 2016</a> the Endocrinology Subcommittee again requested PTAC reconsider their previous recommendation</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2016-11.pdf"" target=""_blank"">November 2016</a> PTAC again reviewed micronised progesterone, where it noted that the only evidence that PTAC had not seen previously cited by the Endocrinology Subcommittee (<a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2016-06.pdf"" target=""_blank"">June 2016</a>) was the Dartois et al. (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Int J Cancer 2016;138:2415-27</a>) study, and PTAC requested that this be presented at a future PTAC meeting</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">March 2021</a> the Endocrinology Subcommittee assessed this application, recommending that access to micronised progesterone for menopause hormone therapy be widened by removing the funding restrictions, with a high priority within the context of treatment of endocrine disease.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that progesterone in combination with oestrogen is used to treat the symptoms of menopause, and that there are significant health risks in women in with an intact uterus if oestrogen is used unopposed, particularly the increased risk of endometrial cancer. The Committee noted that oestrogen is usually combined with a synthetic form of progesterone, which is associated with its own risks, namely an increase in thromboembolic events and breast cancer.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that the product being considered for this application is a natural micronised progesterone derived from yams which has all the properties of endogenous progesterone, in particular gestagenic, antiestrogenic, slightly anti-androgenic and anti-aldosterone effects. The Committee noted that micronised progesterone is Medsafe approved and is indicated for adjunctive use with an oestrogen in postmenopausal women with an intact uterus for hormone replacement therapy and that the usual dose is 200 mg per day at bedtime at least 12 to 14 days per month, i.e. on days 15 to 26 of each cycle or in the last 2 weeks of each treatment sequence of oestrogen therapy followed by approximately one week without any replacement therapy.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that at its 2021 meeting, the Endocrinology Subcommittee considered that micronised progesterone lowers an individual’s risk of breast cancer cardiovascular disease, mood fluctuation, stroke, and clotting, compared to currently funded synthetic alternatives. The Committee noted that evidence for the use of micronised progesterone comes primarily from the E3N cohort study of 98,995 women initiated in France in 1990 to investigate the risk factors associated with cancer and other non-communicable diseases (<a href=""https://pubmed.ncbi.nlm.nih.gov/26756677/"" target=""_blank"">Dartois et al. Int J Cancer 2016;138:2415-27</a>).</p><p>The Committee noted that the Dartois et al. study reported post-menopausal breast cancer cases as follows; 108 cases in those taking oral oestrogens only (108/1747 participants; hazard ratio (HR) 1.07; 95% CI 0.92 to 1.23), 296 cases in those taking oral oestrogens with progesterone/dydrogesterone (296/4621 participants; HR 1.20; 95% CI 1.09 to 1.32), and 412 cases in those taking oral oestrogens with other progestogen (412/5253 participants; HR 1.72; 95% CI 1.57 to 1.88).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of a systematic review and meta-analysis comparing progesterone with synthetic progestins, each in combination with oestrogens, against the risk of breast cancer and cardiovascular events (<a href=""https://pubmed.ncbi.nlm.nih.gov/27456847/"" target=""_blank"">Asi et al. Syst Rev. 2016;5:121</a>). The Committee noted that this study did not include the Dartois et al. study, and that it reported that progesterone was associated with lower breast cancer risk compared with synthetic progestins when each is given in combination with oestrogen (relative risk 0.67; 95 % CI 0.55 to 0.81).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a systematic literature review on the impact of menopausal hormone therapy (MHT) containing micronised progesterone on the mammary gland (<a href=""https://pubmed.ncbi.nlm.nih.gov/29384406/"" target=""_blank"">Stute et al. Climacteric. 2018;21:111-22</a>). The Committee noted that the review included 19 studies, with multiple reports from the same authors, including relating to the E3N cohort. The Committee noted that the study reported no increased risk of breast cancer for up to five years with the use of micronised progesterone in combination with oestrogen. The Committee also noted, however, that micronised progesterone or dydrogesterone were associated with a slight but significant increase in breast cancer risk after an average of 6 years of treatment duration.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was made aware of a 2020 summary of evidence that stated that it appears that minimal oestrogen is required to initiate the biological processes that promote cancer development (<a href=""https://pubmed.ncbi.nlm.nih.gov/32329768/"" target=""_blank"">Khan S A. JAMA Netw Open. 2020;3:e203608</a>). The Committee considered that the progesterone effect in breast cancer incidence is minor, but that this depends on the type of cancer.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted the following evidence relating to the use of micronised progesterone in the management of menopause symptoms:</p><ul><li><a href=""https://pubmed.ncbi.nlm.nih.gov/27898258/"" target=""_blank"">Yang et al. Gynecol Endocrinol. 2017;33:87-92</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/29570359/"" target=""_blank"">Scarabin PY. Climacteric. 2018;21:341-45</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/22024394/"" target=""_blank"">Canonico et al. Maturitas. 2011 Dec;70:354-60</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/28898378/"" target=""_blank"">Manson et al. JAMA. 2017 Sep 12;318:927-38</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/27548404/"" target=""_blank"">Palacios et Mejía. Expert Opin Drug Saf. 2016 Nov;15:1515-25</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/28650869/"" target=""_blank"">The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. Menopause. 2017 Jul;24:728-53</a></li><li>Baber et al. Climacteric. 2016 Apr;19:109-50</li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/29583019/"" target=""_blank"">Warren. Climacteric. 2018 Aug;21:355-357</a></li><li><a href=""https://www.imsociety.org/2021/02/25/progestogen-progestin-progesterone-why-all-the-confusion-webinar/"" target=""_blank"">International Menopause Society Webinar. March 23 2021</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/22432812/"" target=""_blank"">Gompel. Climacteric. 2012 Apr;15 Suppl 1:18-25</a></li><li><a href=""https://pubmed.ncbi.nlm.nih.gov/24223752/"" target=""_blank"">Cordina-Duverger et al. PLoS One. 2013 Nov 1;8:e78016</a></li><li><a href=""https://journals.lww.com/menopausejournal/Abstract/2017/07000/The_2017_hormone_therapy_position_statement_of_The.5.aspx"" target=""_blank"">The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. Menopause. 2017;24:728-53</a></li></ul><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence suggests that the risk of venous thromboembolism increases by about one half with synthetic progesterone, and that synthetic progesterone has an androgenic effect which increases cardiovascular risk. The Committee noted that micronised progesterone does not have this androgenic activity and thus might be expected to not increase cardiovascular risk. The Committee also noted that in France studies have been published widely on the use of micronised progesterone reducing side effects such as bloating, mood swings, depression and acne. The Committee noted that the increased risk of breast cancer from existing MHT treatments persists for more than 10 years following discontinuation of treatment, and that those women who used MHT for 10 years had double the chance of developing breast cancer than those who used it for only 5 years (<a href=""https://pubmed.ncbi.nlm.nih.gov/31474332/"" target=""_blank"">Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 2019;394:1159-68</a>).</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that risks relating to endometrial cancer were not discussed at the 2021 Endocrinology Subcommittee meeting. The Committee noted a publication investigating the risk of endometrial cancer associated with different hormone replacement therapies in the E3N cohort (<a href=""https://pubmed.ncbi.nlm.nih.gov/25008104/"" target=""_blank"">Fournier et al. Am J Epidemiol. 2014;180:508-17</a>). The Committee noted that 301 endometrial cancers were reported in total, and that the use of micronised progesterone with oestrogen increased the risk of endometrial cancer compared with those who had never used MHT (hazard ratio 1.80; 95% CI 1.38 to 2.34). The Committee also noted that the risk increased with prolonged use; those using micronised progesterone for less than five years had a hazard ratio of 1.30, which increased to 2.66 with use spanning longer than 5 years. The Committee noted, however, that the dose of micronised progesterone in the study was unclear and that many of the patients used micronised progesterone as a vaginal gel. The Committee considered that the dose of micronised progesterone may not have been high enough to mitigate the effect of oestrogen in inducing endometrial cancer.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was made aware of a 3-year multicentre, randomized, double-masked, placebo-controlled trial investigating the risk of endometrial hyperplasia in 596 postmenopausal women aged 45 through 64 years without contraindication to hormone therapy who were randomised to receive either placebo, conjugated equine oestrogens, conjugated equine oestrogens with medroxyprogesterone acetate, or conjugated equine oestrogens with micronised progesterone (<a href=""https://pubmed.ncbi.nlm.nih.gov/8569016/"" target=""_blank"">Judd et al. JAMA. 1996;275:370-5</a>). The Committee noted that patients receiving oestrogens in combination with progesterone did not have an increased rates of endometrial hyperplasia compared to placebo (P=0.16). The Committee considered that pharmacoepidemiology studies are a more reliable source of information regarding development of rare adverse events over time than randomised controlled trials.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee were made aware of a study investigating the association of various types of hormone therapies with the risk of endometrial cancer among postmenopausal women recruited into the European Prospective Investigation into Cancer and Nutrition between 1992 and 2000 (<a href=""https://pubmed.ncbi.nlm.nih.gov/20961969/"" target=""_blank"">Allen et al. Am J Epidemiol. 2010:172:1394-403</a>). The Committee noted that of 115,474 women in the study, 601 developed endometrial cancer, and that 81% of these cases were verified. The Committee noted that the hazard ratio associated with micronised progesterone was 2.42, compared with 1.73 with synthetic progesterone (95% CIs 1.53 to 3.38 and 0.84 to 1.97, respectively). The Committee considered that this study had a low risk of selection bias, a moderate risk detection bias, high internal validity, and was of moderate quality.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of progesterone and endometrial cancer which included 11 randomised controlled trials and 14 observational studies (<a href=""https://pubmed.ncbi.nlm.nih.gov/27451318/"" target=""_blank"">Sjögren et al. Maturitas. 2016;91:25-35</a>). The Committee noted that micronised progesterone increased the risk of endometrial cancer, especially when used continuously (former use of micronised progesterone was associated with a hazard ratio of 1.44 [95% CI 0.99 to 2.08] compared with 2.42 with ‘current use’ [95% CI 1.53 to 3.83]). The Committee noted that other types of progesterone did not seem to affect the risk of endometrial cancer.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of MHT and the risk of endometrial cancer that included 31 papers, only two of which were randomised controlled trials, and also included the Sjogren et al. and Allen et al. papers (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465414/pdf/cancers-12-02195.pdf"" target=""_blank"">Tempfer et al. Cancers (Basel). 2020;12:2195</a>). The Committee noted that short term use of micronised progesterone (5 years or less) was not associated with an increased risk of endometrial cancer. The Committee noted that the randomised controlled trials in this review did not adjust for confounders and were of low precision, and that some of the studies included were funded by drug manufacturers. The Committee also noted that very few studies excluded the possibility of cancer hyperplasia at enrolment, and that the majority of participants in the studies self-reported exposure to the study drugs, which carries the risk of detection and recall bias. The Committee considered that studies with a single baseline exposure categorisation carry a classification bias, as some women may have used different hormone formulations.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was made aware of a study investigating the ethnic-specific trends in endometrial cancer across different age groups in New Zealand (<a href=""https://pubmed.ncbi.nlm.nih.gov/30671687/"" target=""_blank"">Scott et al. Cancer Causes Control. 2019;30:121-27).</a> The Committee noted that there has been a gradual increase in endometrial cancer registrations in New Zealand since 1996, and that Pacific women have the highest registered incidence.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that body mass index (BMI) is a strong indicator of endometrial cancer risk and that the association is no longer clear among users of MHT (<a href=""https://pubmed.ncbi.nlm.nih.gov/18187388/"" target=""_blank"">McCullough et al. Cancer Epidemiol Biomarkers Prev. 2008;17:73-9</a>). The Committee noted that use of MHT has been associated a reduced risk of endometrial cancer due to being high BMI/obesity, and that this association does not differ between continuous and sequential therapy (<a href=""https://pubmed.ncbi.nlm.nih.gov/21030602/"" target=""_blank"">Crosbie et al. Cancer Epidemiol Biomarkers Prev. 2010;19:3119-30</a>). The Committee also noted that in a large US cohort study that those with a BMI of over 30 had a relative risk of developing endometrial cancer of 5.41 compared to those with a BMI under 25 in those who had never used MHT, compared to a relative risk of 2.35 amongst those who had formerly used MHT (<a href=""https://pubmed.ncbi.nlm.nih.gov/17416763/"" target=""_blank"">Chang et al. Cancer Epidemiol Biomarkers Prev. 2007;16:723-30</a>). The Committee noted that progestagens are considered to potentially counteract the adverse effect of oestrogens on the endometrium,\xa0that association between progestagen use and endometrial cancer risk being greater the more days every month that progestagens are added to oestrogen and the more obese that users are (<a href=""https://pubmed.ncbi.nlm.nih.gov/15866308/"" target=""_blank"">Beral et al. Lancet. 2005;365:1543-51</a>).</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence suggests that currently funded MHTs carry an increased risk of breast cancer, though the evidence is mixed, and that the effect of MHT on breast cancer is likely to differ according to the type of breast cancer. The Committee considered that if there is an increased risk of breast cancer, that it is likely the risk increases with duration of treatment and persists after discontinuing treatment. The Committee considered that micronised progesterone may also carry an increased risk of breast cancer (compared to non-users of MHT) but the extent of this increased risk was marginal, and micronised progesterone was probably associated with lower risks when compared with synthetic progesterone. However, the Committee considered the lack of published evidence reporting mortality benefits of micronised progesterone limited conclusions about differences in breast cancer risk.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that overall, micronised progesterone carries an increased risk of endometrial cancer and breast cancer, although the breast cancer risk associated with micronised progesterone is lower than with other MHT therapies. The Committee noted that breast cancer incidence in New Zealand is much higher than endometrial cancer, and considered that any decrease in breast cancer incidence would be beneficial for patients and the health system and thus any relative reduction in breast cancer incidence would outweigh a potential increase in endometrial cancer. The Committee considered that there was no evidence to indicate if the increased risk of endometrial cancer persists beyond treatment discontinuation. The Committee considered that the increased endometrial cancer risk may also be manageable in many cases if patients present with low grade endometrial cancer, as this can be resolved through withdrawal of the agent.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that while there was uncertainty in the magnitude of difference in breast cancer risk between agents, it was likely that micronised progesterone may be associated with an improved side effect profile vs synthetic progesterone. The Committee considered that it was unlikely micronised progesterone was superior with regard to mood fluctuations vs currently funded MHTs.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a recent UK study which reported 14 million workdays lost annually by women suffering from symptoms of menopause, and that 25% of women going through menopause consider leaving work due to their symptoms (<a href=""https://www.burnesspaull.com/__data/assets/pdf_file/0019/13159/Menopause-in-the-Workplace_print.pdf"" target=""_blank"">Burness Paul report: Menopause in the Workplace. 2019</a>). The Committee considered that it is important to have options for patients who cannot tolerate the currently available funded options.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if micronised progesterone were to be funded for this indication nearly half of women would switch to this from synthetic progesterone, and that women who do not take MHT due to the breast cancer risk, may be more likely to start treatment if micronised progesterone were available. The Committee also considered that it is likely that all women initiating MHT would start on micronised progesterone. The Committee noted that uptake of MHT in the Māori and Pacific community is low and considered that a different treatment option may increase use in these communities. The Committee noted, however, that the reason for the decreased up take in these communities is likely attributable to a variety of factors, including perceived safety concerns, intolerance issues and access inequities, and that the lower uptake is unlikely to be purely a function of insufficient treatment options. The Committee considered that uptake may also be higher than predicted due to micronised progesterone being ‘natural’ and the perceived and actual benefits of this over synthetic progesterone.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that MHT uptake has been reducing over time, and this may be due to the perceived safety concerns around MHT treatment. The Committee considered that funding a new option that is not perceived to carry the same risks of breast cancer could help improve uptake of MHT. The Committee considered that improved uptake of MHT would improve quality of life and may be associated with fewer women having severe symptoms that force them to stop paid work.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the number of additional women who may access MHT (and are not currently receiving MHT) if micronised progesterone were funded is uncertain. The Committee noted that uptake of MHT is much lower in New Zealand compared to overseas and considered that attitudes towards MHT are significantly different overseas and thus difficult to compare to New Zealand. The Committee estimated that it may be reasonable to assume an increase in the number of MHT-treated patients of up to 20% and considered that there is unlikely to be a large pool of patients not receiving treatment who will switch to micronised progesterone.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that micronised progesterone is currently listed for the prevention of pre-term labour, and that it is also used in other countries for amenorrhoea and assisted reproductive technology. The Committee considered that if micronised progesterone were to be open listed that it would be used more widely for indications other than MHT for menopause, but that the increase in uptake from these other groups could not be predicted accurately. The Committee considered that the usage in these other indications would likely be small in comparison to the usage in managing menopausal symptoms.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the below table summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for micronised progesterone if it were to be funded in New Zealand for menopause. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><table class=""ql-table-blob"" border=""0"" style=""width: 460.45pt;"" width=""614""><tbody><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal"" style=""""><b>P</b><span style=""color: black;"">opulation </span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style="""">Menopausal patients requiring\n  menopause hormone therapy (MHT)</p><p class=""MsoNormal"" style="""">A small number of patients\n  accessing micronised progesterone for other indications if listed without\n  restriction</p></td></tr><tr style=""height: 81.15pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 81.15pt;"" width=""100""><p class=""MsoNormal"" style=""""><b><span style=""color: black;"">I</span></b><span style=""color: black;"">ntervention</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 81.15pt;"" width=""514""><p class=""MsoNormal"" style="""">Micronised progesterone, dosing\n  either:</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>100mg/day\n  on days 1-25 each month, or</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>200mg/day\n  on days 15-26 each month</p><p class=""MsoNormal"" style="""">\xa0</p><p class=""MsoNormal"" style="""">Mean duration of use 4.2 years, with\n  ~44% requiring &gt;5 years of treatment (<a href=""https://academic.oup.com/aje/article/180/5/508/2739102?login=true"" target=""_blank"">Fournier et al. Am J Epidemiol\n  2014;180: 508-17</a>)<i><span style=""font-size: 11.0pt;""></span></i></p></td></tr><tr style=""height: 49.0pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 49.0pt;"" width=""100""><p class=""MsoNormal"" style=""""><b><span style=""color: black;"">C</span></b><span style=""color: black;"">omparator(s)</span></p><p class=""MsoNormal"" style=""""><span style=""color: black;"">(NZ context)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 49.0pt;"" width=""514""><p class=""MsoNormal"" style="""">Currently funded MHTs; most\n  commonly prescribed include medroxyprogesterone acetate, oestradiol with\n  norethisterone (which is partially funded), oestradiol valerate and\n  ethinyloestradiol</p></td></tr><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal"" style=""""><b><span style=""color: black;"">O</span></b><span style=""color: black;"">utcome(s)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Improved\n  quality of life compared to patients on no treatment</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Efficacy\n  similar to other MHTs in managing menopausal symptoms</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Improved\n  side effect profile vs currently funded MHTs</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Marginally\n  lower<i> </i>risk of breast cancer compared with currently funded MHTs</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Marginally\n  higher risk of breast cancer compared with no treatment, for those patients\n  on treatment for &gt;5 years (<a href=""https://link.springer.com/article/10.1007/s10549-014-2934-6"" target=""_blank"">Fournier\n  et al. Breast Cancer Res Treat 2014;145: 535-43</a>)</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Higher\n  risk of endometrial cancer vs no treatment and vs currently funded MHTs (<a href=""https://academic.oup.com/aje/article/180/5/508/2739102?login=true"" target=""_blank"">Fournier et al. 2014</a>)</p><p class=""MsoNormal"" style=""margin-left: 21.0pt;"">-<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\n  </span>Lower\n  risk of VTEs vs currently funded MHTs (<a href=""https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/412423"" target=""_blank"">Huerta et al. Arch Intern 2007;167: 935-43</a>)</p></td></tr><tr style=""height: 22.1pt;""><td colspan=""2"" rowspan=""1"" valign=""top"" style=""width: 460.45pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""614""><p class=""MsoNormal"" style=""""><span style=""font-size: 9.0pt;"">Table definitions: Population,\n  the target population for the pharmaceutical; Intervention, details of the\n  intervention pharmaceutical; Comparator, details the therapy(s) that the\n  patient population would receive currently (status quo – including best supportive\n  care); Outcomes, details the key therapeutic outcome(s) and source of outcome\n  data.\xa0 </span></p></td></tr></tbody></table><p><br></p>', 'Status_History__c': 'a132P000000DOnmQAG'}, 'change': None}]",Jun 2012,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2022', 'fs': 'Feb 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztf32AC'}, 'Id': 'a0POZ000002Ztf32AC', 'Event_Date__c': '2022-02-22', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2022', 'Status_History__c': 'a132P000000DYUfQAO'}, 'change': None}]",Feb 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztet2AC'}, 'Id': 'a0POZ000002Ztet2AC', 'Event_Date__c': '2013-11-05', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqVRQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2016', 'fs': 'Jun 2016', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztex2AC'}, 'Id': 'a0POZ000002Ztex2AC', 'Event_Date__c': '2016-06-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2016', 'Status_History__c': 'a132P000000Ar9VQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztf42AC'}, 'Id': 'a0POZ000002Ztf42AC', 'Event_Date__c': '2022-03-04', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000DaQ8QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2022', 'fs': 'Apr 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztf52AC'}, 'Id': 'a0POZ000002Ztf52AC', 'Event_Date__c': '2022-04-29', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Apr 2022', 'Status_History__c': 'a132P000000DifMQAS'}, 'change': None}]",Nov 2013,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-05-19-proposals-to-widen-access-to-progesterone-antiretrovirals-and-nitrofurantoin"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-05-19-proposals-to-widen-access-to-progesterone-antiretrovirals-and-nitrofurantoin"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztf62AC'}, 'Id': 'a0POZ000002Ztf62AC', 'Event_Date__c': '2022-05-19', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-05-19-proposals-to-widen-access-to-progesterone-antiretrovirals-and-nitrofurantoin"" target=""_blank"">Consultation letter</a></p>', 'Formatted_Date__c': 'May 2022', 'Status_History__c': 'a132P000000DlkWQAS'}, 'change': None}]",May 2022,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2022', 'fs': 'Jun 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztf72AC'}, 'Id': 'a0POZ000002Ztf72AC', 'Event_Date__c': '2022-06-02', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Jun 2022', 'Status_History__c': 'a132P000000Dwv8QAC'}, 'change': None}]",Jun 2022,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-09-15-decision-to-open-access-to-progesterone"" target=""_blank"" style=""color: rgb(68, 68, 68);"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-09-15-decision-to-open-access-to-progesterone"" target=""_blank"" style=""color: rgb(68, 68, 68);"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000002Ztf82AC'}, 'Id': 'a0POZ000002Ztf82AC', 'Event_Date__c': '2022-09-15', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-09-15-decision-to-open-access-to-progesterone"" target=""_blank"" style=""color: rgb(68, 68, 68);"">Decision notification</a></p>', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000E3M3QAK'}, 'change': None}]",Sep 2022,False,True
